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Non-union is a devastating complication of fracture and can be precipitated by abnormal 
inflammatory states including infection and diabetes.  
This thesis focuses on four related research problems that are addressed through original 
scientific investigation and literature review. In addressing these questions, this dissertation 
presents evidence for the following conclusions through in vivo animal models and using methods 
including bacterial cell culture and counting, histology, radiography, and micro-computed 
tomography:  
1. Rifampin-loaded hydrogels decrease bacterial load and improve fracture healing in 
a MRSA-infected open fracture model. 
2. MRSA-infected nonunion is characterized by impaired chondrocyte maturation and 
is associated with IL-1 and NF-KB activation. 
3. Local teriparatide improves radiographic fracture healing in a type 2 diabetic mouse 
model, but is inferior to systemic treatment.  
4. Systemic administration of teriparatide, along with systemic antibiotics, improves 
fracture healing in a diabetic, MRSA-infected mouse tibia fracture model. 
This current work is not without limitation, and many aspects of this work are still in 
progress. Nevertheless, the author hopes that this dissertation will serve as providing meaningful, 
foundational data for future laboratory and clinical studies to improve our understanding of 
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I. Overview: Fracture healing is essential to human health  
Unlike repair mechanisms of nearly every other human tissue, bone fracture  
healing has the potential to restore the original structure and physical properties without leaving 
functional deficits, scar, or other evidence of previous injury [1]. The biologic process of fracture 
healing is complex and requires mechanical stability, growth factors, stem cells, and other factors 
in order to restore structure and function [2].  
Successful fracture healing is essential to human health, as fracture is one the most common 
traumatic injuries to humans [1,3]. Fracture nonunion and delayed union results in pain and 
disability, and can be devastating for patient’s quality of life [4-5]. Specifically, in a 2013 study, 
tibia shaft non-union resulted in a negative effect on mental and physical health that was worse 
than congestive heart failure and equivalent to end-stage hip arthrosis [4]. In a similar study, 
Schottel et al found that femoral fracture nonunion demonstrated a reduced quality of life similar 
to type 1 diabetes, stroke, and acquired immunodeficiency syndrome [6]. Forearm and clavicle 
nonunion resulted in the greatest degree of impairment, compared to femur, tibia, fibula, and 
humerus fracture [6].  
Fracture non-union also poses a major burden to our healthcare and economic systems. An 
estimated 100,000 fractures result in non-union in the United States every year [7]. In the US, 
additional healthcare costs due to tibia fracture nonunion range from $11,333 to $13,870 [8-9]. 
Indirect costs of nonunion, most notably productivity loss, account for the majority of the 
economic burden resulting from fracture nonunion. Among Canadian and European healthcare 
systems, these indirect costs make up for an estimated 67-79% and 82-93% of total costs burden, 
respectively [7].  
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The overall fracture nonunion rate is cited to be approximately 5-10% in the orthopaedic 
literature [10-11]. In a 2016 study of open long bone fractures, 17% progressed to nonunion and 
an additional 8% demonstrated delayed union [12]. Non-union risk is variable and depends on 
injury factors such as site, mechanism, and severity; and patient factors such as age, sex, and 
comorbidities [13-14]. The incidence of non-union and delayed union is proposed to have 
increased over the past decades due to improved patient survival and advances in medical and 
surgical care following major injuries [15]. 
Many approaches to improving fracture healing have been investigated, from biologic and 
surgical approaches to traditional medicine practices [16]. This dissertation will discuss 
translational science approaches to improve fracture healing in altered inflammatory environments 
including diabetes and infection. It will discuss the use of a locally-applied hydrogel to deliver 
antibiotics and teriparatide under inflammatory conditions, using mouse models of infected 
nonunion and diabetes. It will also identify key cellular processes and potential avenues for 
targeted therapies. It is the author’s hope that these findings will enhance our understanding of 
fracture non-union and move the field of orthopaedic surgery forward by providing a basis for 
future clinical investigations.  
 
II. Bone quality in health and disease1 
 
Successful fracture healing and underlying bone quality are closely related. Mesenchymal stem 
cells, chondrocytes, osteoblasts, osteocytes, and osteoclasts form a tightly-regulated cellular 
network that performs in the tasks of building and maintaining bone as well as fracture healing. 
                                                     
1 Based on: SC, Lee, FY. “Orthopaedic Tissues,” Orhtopaedic Knowledge Update 13, AAOS 
2020. All text and figures in this thesis, including hand drawings, are original and were prepared 
by the author, unless explicitly noted. The author acknowledges Dr. Lee’s guidance in preparing 
and revising this portion of the text.  
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Hormonal regulation is essential, with mesenchymal progenitor cells playing major signaling roles. 
This section will investigate the normal workings of this cellular network of orthopaedic tissues 
and how it can fail in diseased states such as smoking and cancer. This section will present basic 
components of bone biology that are relevant to fracture healing, diabetic bone disease, 




Figure 1. Major transcription factors and regulators of bone cell differentiation 
 
Mesenchymal stem cells differentiate via a stepwise progression into chondrocytes, adipocytes, 
osteoblasts, osteocytes, tenocytes, and myocytes. Osteoclast arise from the monocyte lineage of 
hematopoietic stem cells. A host of transcription factors, genes, and growth factors regulate 
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differentiation. Activation via RANK-L and inhibition by OPG, both expressed by pre-osteoclasts, 
are major regulators for osteoclastogenesis. 
 
Orthopaedic tissues are derived from pluripotent stem cells which become increasingly 
more specialized (figure 1). Bone is unique in that regulation of cellular and metabolic processes 
occur primarily at the level of the stem cell. Osteoblasts, chondrocytes, adipose cells, fibroblasts, 
and myocytes share the mesenchymal stem cell as the common precursor, while osteoclasts are 
derived from the macrophage/monocyte lineage of hematopoietic stem cells. Altered development 
and function of these precursor lineages underly many of the processes that alter bone quality and 
fracture healing potential.  
Variable expression of transcription factors facilitates stem cell differentiation into 
terminal lineages to form orthopaedic tissues as cellular migration and ossification take place [17]. 
Runx2 and osterix are essential for differentiation of the osteoblast lineage. Sox5, 6, and 9 are 
markers of chondrocyte development, with Sox9 having been identified as an essential regulator 
[18] (Figure 1). These signaling pathways involved in mesenchymal stem cell differentiation have 
important consequences for fracture healing under infected conditions (pages 75-80, 97-100). The 
Wnt/-catenin pathway is one of the most important signaling pathway for regulating bone 
formation, leading MSCs towards osteoblastic differentiation and suppressing adipose 
development, and is altered in diabetes (page 42).  
Ossification is a foundational principle that underlies both skeletal development and 
fracture healing. During human development, contact between mesenchymal cells and epithelial 
cells triggers pre-osteoblastic differentiation and intramembranous ossification, during which 
mesenchymal cells differentiate directly into periosteum and osteoblasts [19]. During 
 11 
endochondral ossification (Figure 2), mesenchymal tissue develops into bone from a cartilage 
template [20]. Chondrocytes proliferate and undergo hypertrophy and apoptosis, and the remaining 
matrix is mineralized and invaded by vasculature. Systemic factors, such as growth hormone and 
thyroid hormone, and local factors such as Indian hedgehog and PTHrP, promote and regulate 
these processes (Figure 2). Woven bone, secreted by osteoblasts, is eventually replaced by 
lamellar bone.  After a rudimentary skeleton is formed, osteoblasts and chondrocytes undertake 
skeletal modeling to shape the skeleton and improve its strength and resilience. More information 
about the ossification process as it relates to fracture healing can be found on pages 23-26.  
Secondary ossification widens bones, with peripheral growth from the apophysis.  In 
contrast to primary ossification, which begins in the embryonic stage and continues through 
adolescence, secondary ossification only begins during the post-natal period. 
Bone Cellular Biology. Bone is a rich, biologically active tissue. Osteoblasts, osteocytes, 
and osteoclasts maintain and renew the bony matrix and are involved in systemic processes such 
as mineral metabolism. An understanding of bone cellular biology is essential for understanding 
the mechanisms behind fracture healing and diabetic bone disease. 
Mature osteoblasts contain abundant rough endoplasmic reticulum for collagen synthesis, 
as well as an extensive Golgi apparatus. Osteoblasts synthesize bone through type I collagen 
secretion and production of osteoid (unmineralized matrix). Parathyroid hormone stimulation and 
Runx2 expression induce the expression of alkaline phosphatase, type 1 collagen, and bone 
sialoprotein II in the preosteoblast stage [21] (Figure 1). Transcriptional activation of RUNX2 and 
osterix result in osteoblast differentiation, allowing for matrix mineralization and expression of 
other proteins such as osteocalcin to occur. Experimental evidence for the importance of RUNX2 
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in fracture healing is given on page 75-81. Osteoblasts create a basic environment with alkaline 
phosphate that helps catalyze calcium-phosphate crystal deposition. 
 
Figure 2. Endochondral Ossification and Cartilage Differentiation 
Endochondral ossification occurs at the physis, during which chondrocytes undergo proliferation, 
hypertrophy, and apoptosis. The matrix left behind is mineralized and invaded by blood vessels. 
Growth factors, including growth hormone, thyroid hormone, and FGF3, promote osteogenesis. 
Indian hedgehog and PTHrP create a feedback loop to modulate and regulate chondrocyte 




Osteocytes, which comprise over 90% of all bone cells in adults, are differentiated from 
osteoblasts [22]. Our understanding of osteocytes has dramatically increased over the past decade, 
especially our understanding of the mechanisms of response to mechanical loading and their role 
in bone metabolism. The process of the osteoblast becoming embedded in bone lacunae induces 
changes genetic expression to induce osteocyte differentiation, including participation in 
mineralization regulation and development of dendritic processes [22]. The expression of 
membrane type 1 matrix metalloproteinase is necessary for canaliculi formation, through which 
osteocytes form an extensive intercellular network of dendritic processes that directly 
communicate via gap junctions [23]. The lacunar-canalicular system contains circulating fluid that 
provides osteocytes with oxygen and nutrients and allows osteocytes to sense acute deformation 
of the bone matrix, inducing release of anabolic factors to increase bone mass in response to strain. 
These lacunar networks are significant in the setting of osteomyelitis, as it will be shown (Page 
75) that the lacunae are the main harboring site of bacteria following MRSA-infected fracture. 
Osteocytes are important regulators of bone metabolism. In addition to sensing fluid 
microcurrents and responding to bone matrix strain, osteocytes produce sclerostin and Dkk1, 
which are potent Wnt inhibitors and therefore key negative regulators of osteoblastogenesis [22].  
Sclerostin and Dkk1 monoclonal antibodies are under investigation as a potential means of 
increasing bone mass and improving fracture healing, especially in diabetes [24]. A more thorough 
discussion of the roles of sclerostin and Dkk1 in the altered inflammatory environment of diabetic 
bone disease is provided on page 42. 
Osteoclasts, derived from hematopoietic stem cells, appear as large, multinucleated cells 
housed in Howship’s Lacunae, microscopic grooves on the bone surface. The ruffled border seals 
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the bone surface, creating a closed microenvironment in which degradation products such as acid 
(produced by carbonic anhydrase and H+ ATPase) and cathepsin K degrade the bone matrix [25].  
Osteoclast development and differentiation is tightly linked to the osteoblastic lineage, and 
dysregulation leads to bone pathology (Figure 1). Commitment to the osteoclastic lineage from 
hematopoietic precursors is induced by macrophage colony stimulating factor, c-fos transcription 
factor, and RANK expression [26]. RANK-ligand, expressed by osteoblasts, is required for pre-
osteoclast differentiation into osteoclasts. Osteoprotegerin (OPG), produced by cells of the 
osteoblast lineage as well as some hematopoietic cells, serves as a decoy receptor for RANK-L 
and competes with osteoclast RANK receptor; increased OPG decreases osteoclast differentiation 
and activation. Systemic factors help to regulate RANK-L and OPG production, including TNF-
, a catabolic factor, and PTH and estrogen, anabolic factors. Factors that contribute to osteoclast 
activation are found in the setting of infected fracture (pages 27-29).  
 Although osteoclast differentiation is tightly regulated by the osteoblastic lineage, 
osteoclast activity is also influenced by hormones.  Resorptive activity is increased by vitamin D, 
PTH, PTHrP, and prolactin, and decreased by estrogen, calcitonin, and TGF-. Cytokines also 
regulate osteoclast activity. IL-17 has been shown to decrease bone resorption; IL-6 and TNF- 
increase resorption [26]. Parathyroid hormone is the main anabolic agent studied in this 
dissertation, and is used to improve fracture healing in normal and diabetic mice. More detail about 
the action of parathyroid hormone can be found on pages 49-50. 
 Marrow adipocytes have long considered inert place holders in the marrow space of long 
bone, ribs, sternum, and vertebrae. However, marrow fat has been increasingly recognized as an 
important, active element of the bone cell milieu and is considered a distinct type of adipocyte (as 
opposed to white, brown, or beige fat found elsewhere in the body). As discussed in a 2017 study, 
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it has been shown that marrow adipocytes increase with age and are tightly correlated with reduced 
bone mass [26]. These regulatory effects on bone mass are thought to be induced through 
modulation of PPAR and RUNx2 proteins [27]. Thus, marrow adipocytes and associated 
signaling pathways have become sought-after targets for bone disease therapies. In addition to 
bone metabolism, it is thought that marrow adipocytes influence other cell populations within the 
marrow and negatively affect hematopoiesis [26]. The adipocyte lineage is important to the 
pathogenesis of diabetic bone disease, as discussed on page 44. 
Matrix Composition. The cellular components produce and maintain a mineralized bone 
matrix, which serves as the functional component of bone. The extracellular matrix is 
heterogeneous and structured. Mineral and organic components together impart strength and 
rigidity (Table 1a). The composition of bone varies with age, gender, and ethnicity. Health status 
can also affect matrix composition, and alterations of the matrix underlie diseases such as 
osteogenesis imperfecta and osteoporosis [28]. 
The mineral calcium hydroxyapatite, Ca10(PO4)6(OH)2, is the most abundant substance in 
bone, 60-70% of its mineral composition. Other abundant minerals include sodium, magnesium, 
and bicarbonate [28]. The organic component of bone, or osteoid, stabilizes the extracellular 
matrix, facilitates calcification and mineralization, and provides tensile strength.  Type I collagen 
is the dominant organic substance of bone, comprising 90% of total protein and the second most 
abundant substance following hydroxyapatite.  The collagen triple helix, characterized by glycine-
X-Y repeating sequence, is highly crosslinked, providing elasticity. Fibronectin, another important 
structural protein of the bony matrix, helps develop and maintain the structure of the collagen 
network. Non-collagenous proteins, such as proteoglycans and osteocalcin, also play various roles 
[29] (Table 1). The quality of bony matrix is determined by a number of factors, but one crucial 
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factor is accumulation of advanced glycosylation end products (AGEs) that occurs in the setting 
of diabetes; a detailed discussion is provided on page 40-41 and figure 9.   
 Bone metabolism: As impact and activity imparts microscopic damage, osteoclasts and 
osteoblasts work in concert to remove old bone and replace it with new bone to maintain strength 
and integrity. This process of remodeling is ongoing, working to replace approximately 10% of 
the skeleton every year and replacing the entire bone mass every ten years [30].  
Remodeling is a tightly regulated process, as osteogenesis is intimately coupled to 
osteoclastogenesis. Remodeling imbalances can result in systemic disease such as osteoporosis as 
well as local bone destruction as in cancer metastasis. Bone loading affects the rate of bone 
remodeling as stated by Wolff’s Law, that mechanical stress results in greater bone density and 
strength. Systemic and hormonal factors, such as parathyroid hormone and 1,25-dihydroxy vitamin 
D, modulate remodeling by inhibiting bone resorption and promote differentiation of osteoblasts 
and osteoclasts [31-32]. Direct communication between osteoblasts and osteoclasts is also 
achieved through release of local factors from the bone matrix itself. As osteoblasts degrade the 
bony matrix, proteins including TGF-, platelet-derived growth factor, and fibroblast growth 
factor are released to stimulate osteoblasts and thus enhance bone formation. Micro-RNA 
modulation has also been identified as a significant regulator of bone remodeling [33]. Bone 
remodeling is essential not only in normal skeletal maintenance, but also in the later stages of 
fracture healing; more detail can be found on pages 24-25. 
Anatomy and Structure. Long bones allow for mechanical motion of the extremities and 
are formed by endochondral ossification (Figure 2). The epiphysis, covered by articular cartilage, 
forms joint surfaces (Figure 3). The physis, distal to the epiphysis, is the location of endochondral 
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ossification, and is located between the epiphysis and the metaphysis. The apophysis, a feature of 
both long and flat bone, is an area of secondary ossification.  
Periosteum is a thin, membranous tissue that surrounds both long and flat bones, and 
endosteum is the corresponding inner surface. The periosteum contains a rich vasculature that 
provides primary blood supply to bone, making it essential for fracture healing. It is also the site 
of muscle and tendon attachment. 
Cortical bone is dense, compact tissue which functions to provide mechanical rigidity. 
Haversian canals run parallel to the diaphysis along the mechanical axis of bone. These spaces 
house nerves and microvasculature that supply the bone tissue. Laminae are discreet, concentric 
sheets of bone that surround the Haversian canal. Volkmann canals allow for communication 
between periosteal vessels and Haversian system. Osteocytes are housed in lacunae and their 
dendritic processes communicate via small canaliculi. Cutting cones comprise the remodeling unit 
of cortical bone, with osteoclasts forming a canal along the longitudinal axis of bone and 
osteoblasts following to close the gaps [32]. The mouse, an animal model used to fracture healing 
under inflammatory conditions throughout this dissertation, lacks the haversian system found in 
human bones.  
Trabecular (or cancellous) bone is a lower-density tissue. Trabecular bone has a porous, 
sponge-like structure which houses marrow elements, including hematopoietic stem cells and 
marrow fat. Remodeling occurs directly on the surface of the trabeculae, with osteoclasts forming 
lacunae which are subsequently filled by osteoblasts [32]. The trabecular network can be assessed 
by micro-computed tomography, a major method used to assess the quality of fracture healing in 







Figure 3. Anatomy of Long Bone 
The major regions of long bone include the epiphysis (nearest to the joint), physis, metaphysis, 
and diaphysis. Blood supply via nutrient arteries is derived from the periosteum, which is also a 





Cartilage, synovial membrane, and synovial fluid compose synovial joints. Together, they 
provide lubrication and protection of joint surfaces and allow for movement along a virtually 
frictionless surface. Inflammation and degradation of these tissues underlie arthritic processes and 
result in debilitating pain and deformity. Interleukin 1 (IL-1), is a major inflammatory mediator 
that has been demonstrated to cause cartilage destruction in osteoarthritis. A more complete 
discussion of the proposed role of chondrocyte differentiation and IL-1 in fracture healing and 
infected nonunion is provided on page 97.  
The chondrocyte is the cellular component of cartilage, and is crucial to fracture healing. 
A major portion of this dissertation is devoted to characterizing changes in chondrocytes and 
cartilage in the setting of infected fracture (pages 75-80, 97-100). The chondrocyte comprises only 
a small amount of total articular cartilage mass, approximately 5% of its dry weight. Cartilage is 
composed primarily of water and cross-linked type II cartilage, secreted by chondrocytes (Table 
1). Proteoglycans, most abundant in the deep layer, trap fluid and contribute to pressurization and 
compressive tissue strength. SOX5 and SOX6 expression, along with interactions with 
CEBP/p300, stimulate chondrocytes to secrete type II collagen and proteoglycans [34]. In addition 
to secretion, chondrocytes regulate cartilage homeostasis by expression of metalloproteinases that 
break down the cartilage matrix. Components of the cartilage extracellular matrix, especially type 
XI collagen, have been identified in a 2017 study as playing a role in inducing chondrogenesis 
[35].  
Chondrocytes undergo terminal differentiation through the process of hypertrophy, marked 
by cellular swelling, decreased proliferation, and eventual apoptosis. While chondrocyte 
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hypertrophy and death allow for bone formation in developing bone, a 2018 study reported that 
hypertrophy has been shown to be an essential step in the pathogenesis of osteoarthritis and marks 
the beginning of irreversible degradation to the cartilage matrix [34]. 
 The quality of tissues including bone, cartilage, and ligaments plays a significant role in 
prevention and treatment of skeletal disease. Physiologic causes, such as age, and pathologic states, 
such as diabetes mellitus and metastatic bone disease, can decrease the integrity of these tissues, 
resulting in increased fracture incidence and decreased surgical outcomes. A host of drugs, such 
as corticosteroids, can also affect bone quality.  
Bone health and bone density can be affected by a host of physiologic, pharmacologic, and 
demographic factors that affect the balance of bone resorption and formation (Figure 4). While a 
comprehensive review of causes of impaired skeletal health are out of the scope of this 
introduction, a few key subjects, including aging, malignancy, and smoking are included here, as 
they are common in the clinical setting affect fracture risk and healing potential. A thorough review 
of the role of diabetes, a major focus of this dissertation, is provided on pages 37-51.  
Aging: Aging bone is characterized by decreased bone mass due to progressively 
dysregulated remodeling. With increasing age, the amount of new bone formed with each 
remodeling cycle decreases slightly, while the amount of resorbed bone remains constant. This is 
associated with increased osteocyte apoptosis and decreased number of precursor cells. Other 
factors, such as decreased mechanical loading of bone and accumulation of reactive oxygen 
species, may also contribute to decreased osteocyte function. In addition to decreased bone mass, 
the bone quality changes with aging. As discussed in a 2017 study, collagen becomes increasingly 
crosslinked, resulting in bone that is more brittle with a disrupted mineralized matrix [35]. Bones 
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become slenderer with decreased trabecular bone mass, thinning cortices, and changes in center of 
gravity [36]. Overall, these changes contribute to greater risk of fracture in the elderly. 
 
 
Figure 4. Bone Quality Determinants 2 
Bone mass is determined by a balance between bone formation and resorption. Peak bone mass is 




Osteoporosis is a bone disease distinct from aging that is marked by decreased bone 
mineral density, especially in trabecular bone. The hallmark of osteoporosis is fracture 
                                                     
2 Original figure was prepared by Dr. Lee and modified by the author. 
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predisposition, including non-traumatic fractures and vertebral body fractures. While osteoporosis 
is an age-associated disease, it is generally not considered a disease of aging, as osteoporosis can 
(although rarely) affect the young and does not affect all elderly individuals. Treatment generally 
is targeted against bone resorption, and including bisphosphonates, hormone therapy, and 
calcitonin. Anabolic agents, such as teriparatide (recombinant parathyroid hormone), are also used. 
Preventative measures, including weight-bearing exercise and vitamin D supplementation, is also 
recommended for patients at risk of developing osteoporosis. Patients with diabetes can present 
with osteoporosis, especially type 1 diabetics early in life. Please see pages 37-40 for more 
information on diabetes-induced osteoporosis. 
Malignancy:  Bone destruction can be a devastating source of morbidity in cancer. Two 
major causes of bone destruction will be covered here: radiotherapy and metastasis to bone. 
Radiation therapy, common bone and soft tissue tumor treatment, can cause inflammation, 
vascular fibrosis, and reduced tissue circulation. Bone necrosis can result from hypoxic and 
hypovascular conditions, tissue breakdown, and disrupted wound healing [46]. These conditions 
raise the risk for pathologic fracture and allow for development of chronic infections that are poorly 
responsive to systemic antibiotics. A case presentation on fracture and infection following tumor 
resection and radiation therapy can be found on pages 29-35.  
Malignant bone metastases, an incurable progression of a primary tumor, can lead to pain, 
fracture, and hypercalcemia due to dysregulated bone remodeling [47]. Lung, breast, and renal 
cancer, as well as multiple myeloma, are best known for causing osteolysis. A host of pathways 
contribute to tumor-driven bone destruction, including increased expression of RANK-L, matrix 
metalloproteinases, and PTHrP. Tumor cells can also undergo osteoclastic mimicry by fusing with 
osteoclast precursors, gaining the ability to participate in bone resorption. Furthermore, osteolytic 
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matrix destruction facilitates cancer progression via TGF-B release, increase calcium, and 
hypoxia. Prostate cancer bone metastasis, on the other hand, is marked by pathologic production 
of immature, woven bone. Tumor cell epithelial-to-mesenchymal transdifferentiation and 
osteomimicry are the major osteoblastic pathways involved. 
Smoking: Smoking is a leading cause of preventable morbidity and mortality worldwide, 
and has significant, deleterious effects on bone health. Smoking generates reactive oxygen species, 
impairs mitochondrial activity, impairs fibroblast migration, and reduces blood flow to sites of 
injury [48]. Smoking is a risk factor for low bone density, with recent animal models demonstrating 
increased osteoclast numbers and impaired bone growth in response to long-term cigarette smoke 
exposure [49]. Smokers demonstrate greater time to union and impaired chondrogenesis following 
fracture, as well as higher rates of spinal fusion failure and pseudarthrosis compared to non-
smokers [48,50]. In addition to impaired bone integrity, smokers carry significantly increased risk 
of infection following trauma [51].  
 
III. Normal fracture healing is an inflammation-dependent process.3 
 Fracture healing is a complex process that results from tightly-ordered interactions of cells, 
growth factors, and extracellular matrices [52].6 Fracture healing is broadly classified as secondary 
or primary, delineations that refer to underlying healing mechanisms dependent on rigidity of the 
fracture construct. Primary fracture healing occurs when bone fragments are in direct contact with 
one another and are highly stable with minimal strain [52]. Haversian remodeling facilitates 
healing of the fracture site, dependent on osteoclasts and osteoblasts to directly repair the bone 
fragments. Secondary healing is more common, and is characterized by four steps: 1) the initial 
                                                     
3 The author acknowledges the assistance of Yeun-Ho Cheung, PhD, in revising the first two paragraphs of this 
section.  
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inflammatory phase, 2) soft callus formation, 3) hard callus formation, and 4) remodeling [52-54] 
(Figure 5). 
 
Figure 5. Phases of Normal Fracture Healing. 
Schematic of secondary fracture healing, which progresses through step-wise phases to restore 
original strength and shape to bone without leaving a scar. The inflammatory phase is crucial, 
during which the presence of hematoma from disrupted blood vessels forms a clot, attracting 
immune cells and mesenchymal progenitor cells via inflammatory signaling. Soft-callus, primarily 
made of cartilage, bridges the bone gap. New bone formation follows the process of endochondral 
ossification. The bone’s normal shape is returned by remodeling via osteoclasts osteoblasts. 
 
The early inflammatory phase of secondary fracture healing, prior to soft callus formation, is 
considered to be crucial to the entire healing process [55]. Blood vessel disruption in the bone and 
surrounding soft tissue results in hematoma formation, which incites an inflammatory reaction. 
Conversion of fibrinogen to fibrin occurs in the hematoma, allowing for trapping of innate immune 
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cells. These immune cells release chemokines that attract additional cells to the site [55]. Various 
immune cells that are attracted to the injury site secrete growth factors and cytokines such as TNF-
α, IL-1β, IL-6, and MCP-1, recruiting mesenchymal stem cells which originate from the 
periosteum, bone marrow, and systemic circulation [56-57]. The hematoma and inflammatory 
response support chondrogenic and osteogenic differentiation, eventually resulting in soft callus 
formation [53]. Several animal model studies have demonstrated that impairing this initial stage 
can inhibit the entire fracture repair process [58-59]. 
The soft callus is comprised of cartilage and granulation tissue that provides the biologic 
scaffold onto which new bone is formed. Chondrogenic maturation progresses in a step-wise 
fashion to facilitate bone formation, in simlar manner to secondary ossification at the physis. 
Chondrocytes undergo phases of proliferation, hypertrophy, and apoptosis, followed by vascular 
invasion. Osteoblasts produce woven bone upon the scaffold of dead chondrocytes, resulting in a 
hard callus. The fourth phase of secondary fracture healing, the remodeling phase, occurs over a 
longer period of time as osteoclasts and osteoblasts shape and strenghten the bone, eventually 
renewing its original strength, histologic appearance, and, in many cases, shape. 
By its very nature, then, fracture healing is an inflammatory process. Secondary bone healing 
requires the hypoxic, fibrin hematoma to incite an inflammatory phase to recruit immune cells and 
mesenchymal stem cells to the fracture site in order for secondary fracture healing to occur [59-
60]. Without inflammation, secondary fracture healing could not occur.   
 The rest of this dissertation will focus on fracture healing under altered inflammatory 
conditions, where the immune response is changed with abnormal inflammatory signaling. The 
altered inflammatory environment may arise due to inherent disruptions in metabolic and cellular 
processes, such as diabetes, or as a mechanism of defense, as due to infection. Therefore, studying 
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strategies to prevent infection and improve fracture healing in the setting of diabetes will, 
hopefully, lead to improved outcomes in fracture care.  
 
 
IV.  Infection and osteomyelitis: mechanisms and the inflammatory response 
 
Musculoskeletal infection – osteomyelitis and septic arthritis – is a major source of morbidity 
among orthopaedic patients. This section will focus on osteomyelitis, infection of bone, and briefly 
discuss infection mechanisms and the inflammatory response as related to findings in this 
dissertation. 
 Osteomyelitis can occur via hematogenous spread, when bacteria from a distant site travels 
through the blood and seeds in bone, or contiguous spread, when bacteria is inoculated from 
contact with the outside environment, through surgical procedure or trauma [61]. Staphylococcal 
infections, including Staph. aureus Staph. epidermidis, are most common [62-63]. Antibiotics and 
surgical debridement are gold-standard therapies, but osteomyelitis is difficult to treat with a high 
rate of treatment failure [64]. Osteomyelitis is characterized by formation of sequestrum, an area 
of necrotic bone colonized by bacteria along canaliculi [65]. Staphylococcal bacteria also are 
difficult to eradicate due to ability to cause intracellular infection thus evading immune cells, as 
well as formation of biofilms that form a thick, protective physical barrier around bacteria (figure 
6) [66]. Many antibiotics, such as vancomycin, are ineffective against biofilms and intracellular 
Staph [66].  
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Figure 6. Schematic of mechanisms of chronic Staphylococcus osteomyelitis. 
Staphylococcus infections account for the majority of orthopaedic infection and can seed bone via 
hematogenous spread or direct inoculation. Biofilm formation on bone and orthopaedic implants, 
as well as intracellular infection, allow Staph to evade host immune defenses. Chronic 
osteomyelitis is characterized by sequestrum, an area of devitalized bone colonized by bacteria. 
Successful treatment typically requires aggressive sequestrum debridement and antibiotic therapy.   
 
Innate immune mechanisms provide a non-specific, first line of defense against infectious 
organisms, such as Staph in osteomyelitis. These innate immune mechanisms also function against 
non-microbial insults, such as implant wear nanoparticles, making the diagnostic distinction 
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between infectious and non-infectious inflammation difficult [67]. These inflammatory pathways 
act as primary means of defense, but also can promote destruction of host tissues [68]. There are 
various components to this defense including mechanical barriers, cellular defenses, and chemical 
defense. Mechanical barriers include skin, mucus, and cilia that provide physical separation of the 
host from the outside environment. Cellular components include macrophages and neutrophils. 
Monocytes, which share stem cell lineage with osteoclasts, are also involved in the innate immune 
response [69]. A host of proteins and chemical factors, such as cytokines and chemokines, also 
play an important role in response to infection. 
The first step of bone invasion by Staph involves adhesins that bind to the bone extracellular 
matrix components and facilitating uptake into osteoblasts via endosomes [70-71]. A variety of 
toxins and proteins facilitate the escape of Staph from the endosome [72-75]. Bacterial recognition 
occurs by pattern recognition receptors (PRRs), expressed by osteoblasts, osteoclasts, and 
precursor cells [76]. Nod proteins and Toll-like receptors are the best studied PRRs. They 
recognize bacterial components called pathogen-associated molecular patterns (PAMPs), such as 
cell wall molecules including lipopeptides, peptidoglycan, lipoteichoic acid [77-79]. Specific 
receptors have specific signaling properties that result in a variety of downstream inflammatory 
effects. For example, TLR9 functions within the osteoblast endosome to recognize bacterial DNA, 
and downstream signaling results in oxidative damage to induce bacterial killing [80]. TLR2, on 
the other hand, recognizes peptidoglycan and lipoteichoic acid in osteoblasts, and downstream 
effects include release of antimicrobial peptides and cell death [79].  
 While different TLR and Nod receptors may have distinct downstream effects, there are 
common inflammatory signaling pathways of the innate immune system that mediate host defense. 
A crucial pathway is interleukin (IL) 1 signaling, which induces neutrophilic response. Other 
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common inflammatory mediators, including TNF-alpha and IL-6, promote osteoclast 
differentiation and function, via upregulation of RANK-L [81]. IL-1 is well-known for its negative 
effects on bone and was initially named osteoclast activating factor [82]. Other downstream effects 
include NF-KB activation and the MAP-kinase pathway, which mediate a broad array of cytokines 
and chemokines involved in the immune defense and bone destruction [83]. 
 While an in-depth discussion of inflammatory pathways involved in Staphylococcal 
infection is out of the scope of this dissertation, these inflammatory pathways, especially PAMP 
recognition and IL-1 and NF-KB signaling, have importance in the findings of this dissertation. 
Please refer to the results (page 75) and discussion (page 97) sections for further discussion and 
their relevance to infection and inflammatory fracture healing. 
 
V. Consequences of infected fracture: case presentation and treatment approaches4 
Infection is a devastating complication following fracture, posing a significant burden on 
patients, including increased time and cost of treatment and decreased quality of life. The 
following case illustrates the morbidity associated with infection, highlighting the possibility of 
loss of limb. In this case, infection occurred in the setting of poor bone quality and repeated fracture 
secondary to radiation therapy. First, the case will be presented. Second, the case will be used to 
comment on management of osteomyelitis and infected nonunion. 
This case is illustrative of how diminished bone quality (in this case, due to radiation 
therapy for soft tissue sarcoma treatment) resulted in significant morbidity for the patient, and 
ultimately required thigh resection and limb salvage using a rotational tibio-pelvic constrained hip 
                                                     
4 Based on SC et al, “Rotational tibio-pelvic constrained hip arthroplasty: a surgical technique and case report,” JBJS 
Case Connector 2019; 9(4):E0404. The author acknowledges Kristin Yu, BS, for her assistance in editing and revising 
the text, and Christopher Dussik, BS, for his assistance in obtaining and formatting the photographs represented in 
the figures. Case report and images used with permission from the patient. 
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arthroplasty. Radiation therapy can lead to the development of chronic infection [84]. 
Osteonecrosis can also occur in the setting of radiation therapy, and is characterized by hypoxia, 
hypovascularity, tissue breakdown, and disrupted wound healing [85]. These mechanisms are 
similar to hypovascularity and disrupted wound healing seen in diabetes mellitus. As seen in our 
patient, these conditions allow for chronic infection and increase the risk of pathologic fracture 
[86]. 
The patient in this case gave consent to present and publish this case report. 
A twenty-five-year-old male presented with pain, exposed bone cement, and purulent 
discharge through a massive soft tissue defect of the right thigh. Five years prior to presentation, 
the patient had been diagnosed with multi-compartmental epithelioid sarcoma of the proximal right 
thigh with metastasis to the lungs. He had no other prior medical conditions. He was initially 
treated with wide tumor resection and reconstruction using an intercalary allograft bone, as well 
as radiation to the right thigh and chemotherapy. Metastatic lung lesions were treated with 
chemotherapy. Although epithelioid sarcoma is known to be fatal, the disease had been stable 
following primary sarcoma resection. His initial post-operative course was uneventful until one 
year later, when he developed delayed infection caused by methicillin-sensitive Staphylococcus 
aureus (MSSA) leading to bone resorption, fracture, and mechanical instability. This required 
several revision surgeries using an antibiotic-loaded cement spacer, nails, and implants. After a 
blunt trauma over the operated thigh, he developed a massive soft tissue defect through which the 





Figure 7. Right thigh before and after femur resection. (A) Photograph demonstrating patient’s 
condition on presentation, with massive soft tissue defect and wound dehiscence with exposed bone 
cement. The entire right femur was resected along with non-viable tissue, leaving the sciatic nerve 
and femoral vessels intact (B). Photographs by Dr. Lee. 
 
After discussion of the risks and benefits of available surgical options, the patient decided 
to undergo right femur resection with rotational arthroplasty in attempt to debride non-viable, 
infected tissue while avoiding hip disarticulation. A major concern was that absence of ligaments 
and muscle attachments around the reconstructed hip joint that would most likely lead to hip 
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dislocations. Therefore, we decided to also perform a constrained hip arthroplasty. During the 
procedure, the proximal femur bone quality was extremely poor, and it was evident that the hip 
joint could not be preserved. We resected the entire right femur, leaving the sciatic nerve and 
femoral vessels intact (Figure 7B). Pathology confirmed the presence of osteomyelitis of the 
proximal femur, including femoral head and neck, without evidence of recurrent tumor. Cultures 
confirmed the continued presence of MSSA, consistent with previous cultures.  
Next, we rotated the remaining limb externally 180. We then performed a constrained, 
cemented hip arthroplasty, placing the femoral component stem into the externally rotated 
proximal tibia (Figures 8). Although porous ingrowth would have likely led to an acceptable 
result, cement was used for fixation due to history of lower extremity radiation and infection. 
Additionally, we were able to achieve good positioning of the stem in the tibia without any 
mantle defects, allowing for optimized cement fixation. Antibiotic-containing cement was not 
used. 
Following rotational arthroplasty, we sutured the remaining hip abductor muscles and 
hamstring muscles to the knee joint capsule and patellar ligament distally to function as an 
abductor. We also sutured the gastrocnemius muscles to the rectus muscle as a hip flexor. The 
patella was removed, as it caused a pressure point at the hip.  
Post-operatively, the patient achieved good wound healing. Over 18 months of follow-up, 
he was maintained on antibiotic therapy, and there were no signs of recurrent infection with normal 
laboratory studies. Radiographs have shown no evidence of component loosening or implant 
failure (Figure 8).  While the patient will continue indefinitely on antibiotic therapy, we will 
consider stopping antibiotics only after carefully weighing the risks with the patient. We will 
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pursue a full workup including joint aspiration if pain or other symptoms concerning for recurrent 
infection develop.  
The patient was fitted with a prosthetic device 3 weeks post-operatively that is placed over 
his right foot, with the rotated ankle functioning as the knee joint. He underwent a course of 
physical therapy to strengthen the right gastrocnemius, which functions as the extensor for the 
prosthesis. On physical exam, he exhibits good flexion, extension, and abduction of the 
reconstructed limb and the new functional knee. With the prosthesis in place, there is no external 
deformity and leg lengths are equal. The ankle joint is at the level of contralateral knee joint. 
(Figure 8). He ambulates very comfortably without a walking aid and can hop up and down. The 
patient can also run, although it does not feel entirely normal, owing to femur resection. The patient 
remains cancer-free seven years after his initial diagnosis. 
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Figure 8: Follow-up radiographs.  Antero-posterior radiographs one year following rotational 
tibio-pelvic hip arthroplasty. (A) shows well-positioned acetabular and femoral prosthesis 
components with weight bearing, without evidence of loosening or failure. (B) is a leg-length study 
demonstrating orientation of the reconstructed right hip with tibial rotationplasty. The right ankle, 
well-aligned with the left knee, acts as function knee joint with leg prosthesis in place. The 
gastrocnemius and soleus act as the leg extensor mechanism. Functional leg lengths are equal 






Case notes and treatment of osteomyelitis and infected nonunion. 
 Standard treatments for osteomyelitis include wide surgical debridement and intravenous 
antibiotics. However, these measures are often ineffective, as demonstrated in this case [87]. Large 
tissue resection of necrotic tumor tissue is complicated by postoperative infection in 20% of cases, 
and the rate of infection associated with tumor prosthesis ranges from 8-15% [88].  
Hip disarticulation is an accepted option for chronic infection of the proximal thigh [88-
89]. As in our patient case, poor soft tissue integrity is a significant risk factor for failed limb 
salvage [88]. Since recurrent infection of tumor prostheses often results in extended hospitalization 
and high amputation, repeated revision surgery is discouraged [88].  
Devastating for a patient’s quality of life, proximal lower extremity amputation both 
significantly limits mobility and is associated with negative psychosocial effects [89-91]. Although 
prostheses for proximal lower extremity amputations are available, the majority of patients 
following hip disarticulation reject these devices due to awkwardness or intolerance [90-93]. The 
function of our patient’s prosthesis allows the patient to walk, run, and hop with daily use is 
superior to the likely functional outcome had we proceeded to hip disarticulation. Nevertheless, 
studies have determined that increased energy expenditure due to hip disarticulation prostheses is 
not excessive [94]. Little difference in energy consumption parameters, including oxygen uptake 
and consumption, has been identified between patients with prostheses for hip disarticulation and 
those who have undergone rotationplasty [95]. However, it was determined that rotationplasty does 
allow for greater walking speed [95].  
Winkelmann conducted a case study in 1986 employing his modification of the Van Nes 
procedure for proximal tumors of the femur and similarly found excellent functional results [96]. 
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While these patients were treated for malignancy and not chronic infection as in our case, 
Winkelmann reported no recurrence of primary tumor or pulmonary metastasis at two years 
follow-up. Following femur resection, our patient has had no evidence of recurrent infection for 
over eighteen months of follow-up. 
 
  
VI. Open fracture: minimizing infection risk with systemic and local strategies 
 
 
While the previous case illustrates the challenges surrounding treating chronic 
osteomyelitis, prevention strategies are at the forefront of orthopaedic research. In the trauma 
setting, open fracture poses a crucial area for infection prevention, as wound contamination and 
tissue disruption result in a high risk of post-traumatic, contiguous infection.  
Infection rates following open fracture have been reported to be as high as 13.9%, which 
decreases to 2.3% with antibiotic treatment [97]. Infection risk largely depends on the degree of 
soft tissue disruption [98]. Timely administration is the most important factor in improving the 
efficacy of systemic antibiotics [98-99]. While the global infection rate is low following open 
fracture, diabetics, smokers, and patients with high-grade injuries are at increased risk of fracture 
site infection [100-101].  
Staphylococcus is the most common infectious agent following infection, with MRSA 
being particularly difficult to eradicate [102]. As discussed previously, intracellular infection and 
biofilm formation are major mechanisms by which Staphylococcal infections become established. 
Unlike vancomycin, which is typically used to treat MRSA infection, rifampin is effective against 
biofilms and can target intracellular Staphylococcus [103-106]. 
While early administration of systemic antibiotics is crucial for infection prevention in for 
open fracture, local strategies have been implemented to prevent and contain infection. These 
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strategies are particularly important when vascular supply to the injury site is poor, as in the case 
above or in diabetes. Local infection prevention strategies have become common in addition to 
systemic antibiotics, fixation, irrigation and debridement [107]. Antibiotic-loaded cement was first 
advocated for in the 1970s [108-109]. Antibiotic-loaded PMMA beads are widely used in high-
grade, open injuries [110]. Antibiotic powders have also proven effective in reducing infection in 
animal and clinical studies [111-113].  
Hydrogels, typically comprised of a cross-linked collagen network, have recently been 
investigated as a local antibiotic delivery option and have several distinct advantages over powders 
and PMMA. Hydrogels are injectable, do not require full wound exposure, and release antibiotics 
over time [114]. Hydrogels are biodegradable and do not require retrieval, as opposed to PMMA. 
This dissertation investigates the use of hydrogel as an antibiotic delivery mechanism in a mouse 
open fracture model, as well as for local application of teriparatide. 
 
VII. Diabetes is a pro-inflammatory condition that increases fracture risk 5 
 
Diabetes mellitus (DM) is a major health care problem. Hyperglycemia, the hallmark of DM, 
can lead to cardiovascular, nerve, eye, and kidney damage [115]. DM also damages the 
musculoskeletal system by altering bone metabolism, increasing fracture risk, and impairing 
fracture healing [116-119].  
In 2015, the CDC estimated that over 9% of the US population, or 30.3 million people, had 
diabetes [120]. DM can be classified as type 1 (T1DM) or type 2 (T2DM), with T2DM accounting 
                                                     
5 This section and the following section (Diabetic fracture healing) are based on Henderson et al, “Bone quality and 
fracture healing in type 1 and type 2 diabetes mellitus,” JBJS 2019; 101(15):1399-1410. Dr. Henderson provided 
text outline and select references. Dr. Ibe participated in the initial draft of the text and editing. The author 
performed comprehensive literature review, original writing, and all revisions (based on reviewer feedback) of the 
text represented here, with guidance from co-authors, unless explicitly stated. Figures and tables presented in this 
section are original and were prepared entirely by the author. 
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for 90-95% of cases [116,119]. T1DM results from an inability to produce insulin due to 
autoimmune destruction of pancreatic beta cells [115]. Decreased insulin sensitivity and -cell 
dysfunction are characteristic of T2DM [121]. While genetic factors play a role, obesity is 
considered a critical factor in T2DM pathogenesis [121]. The mouse models used in this work are 
of T2DM. 
Patients with diabetes have a higher risk for vertebral and non-vertebral fracture when 
compared to nondiabetic counterparts. People with T1DM have been found to have relative risk 
of fractures of nearly 7%, while those with T2DM have a lower, but still elevated RR of 1.4% 
[123-127].  
Falls are a particular concern in DM, especially among the elderly. Diabetes is associated 
with impaired physical function that increases fall risk such as peripheral neuropathy, poor 
balance, and heart disease [128]. Among elderly women, diabetes was associated with poorer 
physical performance parameters, including one leg standing and get up and go tests [129]. Other 
potential contributing factors to increased fall risk include hypoglycemic episodes, neuropathy, 
retinopathy and neuromuscular impairments [123,130]. 
A common consequence of T1DM is bone loss that can progress to osteoporosis [131]. 
Young, pre-menopausal women may present with reduced bone mass upon clinical diagnosis of 
T1DM, with the incidence of osteoporosis in T1DM patients being 20% [131-132]. Although 
patients with T2DM are also at increased risk of fracture, they often demonstrate normal or 
increased bone density (T2D, spine 0.41 ± 0.01; hip 0.27 ± 0.01), albeit with lower quality bone 
[127,133-135]. It is theorized that this increased bone density in T2DM may result from obesity 
and increased weight placed on an individual’s bones in the context of decreased bone turnover 
[118].  
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Fracture risk assessment can be challenging for patients with DM. Bone mineral density 
(BMD), the trabecular bone score (TBS), and the Fracture Risk Algorithm (FRAX) score are used 
to identify patients at higher risk for fracture [136]. Prospective studies have demonstrated that 
BMD can be useful to assess fracture risk in older patients with diabetes, although BMD 
underestimates fracture risk in diabetic patients compared to non-diabetic controls [137]. The 
FRAX score has also been previously shown to underestimate fracture risk among diabetic patients 
[138], although a more recent version of the tool now includes additional criteria that includes 
diabetes. TBS, a measure of bone microarchitecture, can be used in conjunction with BMD and 
FRAX scoring. Lower TBS scores, which predict fracture risk in osteoporosis, reflect low 
trabecular connections and increased space in the trabecular network [139]. TBS has been shown 
to be decreased in patients with secondary osteoporosis, including T1DM (1.309 ± 0.125 vs. 
1.370 ± 0.127, P = 0.04) and T2DM (1.228 ± 0.140 vs. 1.298 ± 0.132, p = 0.013) [125-126,140]. 
Recent prospective data demonstrates that FRAX, or FRAX adjusted with TBS, is more highly 
correlated to vertebral fracture risk among postmenopausal diabetic patients compared to BMD 
alone and is favorable due to its low cost and wide availability [139,141].  
Diabetic Bone Biology 
The hallmark of diabetic bone disease is decreased bone turnover and functionally weaker 
bone, contributing to increased fracture risk [142-143]. This occurs via a combination of 
mechanisms that alter bone metabolism by disrupting normal balance between osteoclasts and 
osteoblasts, which is normally regulated by mesenchymal precursor differentiation, local growth 
factors, and mechanical stress as discussed previously in this introduction (Figure 1). Limitation 
of osteoblastic differentiation in combination with an increased adipogenesis in the bone marrow 
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leads to micro architectural changes [118]. Additionally, decreased RANKL expression (65–70%) 
observed in diabetes limits bone turnover [124]. 
 
Figure 9: Effects of hyperglycemia and advanced glycation end products on diabetic bone 
quality. Accumulation of advanced glycation end products (AGEs) occurs as the result of non-
enzymatic coupling of glucose to lipids and proteins. AGEs bind to the receptor for AGEs 
(RAGE), resulting in downstream activation of the MAPK/NF- pathway; overexpression of 
cytokines including TNF⍺, IL-1β, IL-6, and reactive oxygen species; decreased osteoblast 
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differentiation and increased osteoblast apoptosis; and increased osteoclast activity. AGEs also 
act directly on osteocytes to increase sclerostin expression, a potent inhibitor of Wnt and 
osteoblast differentiation. AGES directly disrupt the collagen and mineral matrix, resulting in 
weaker, more brittle bone. Finally, AGEs are the underlying cause of microvascular 
complications such as retinopathy and neuropathy, which can contribute to overall fall risk. 
AGEs – Advanced glycation end products; RAGE – Receptor of advanced glycation end products; 
ROS – Reactive oxygen species; SOST – Sclerostin. 
 
Accumulation of advanced glycation end products (AGEs) disrupts bone cellular biology 
and microarchitecture (figure 9). AGEs, which are produced as a result of the patient’s 
hyperglycemic state, are formed when excess circulating glucose undergoes non-enzymatic 
reactions with various proteins and lipids [118,123]. Clinical studies have demonstrated 
correlations between AGEs and increased fracture risk [144-145]. AGEs accumulation and non-
enzymatic glycosylation in bone directly disrupts the bone extracellular matrix by causing 
excessive cross-linking of type I collagen fibrils, increasing bone stiffness and fragility and 
diminishing its biomechanical properties [146].  
DM is a pro-inflammatory state mediated by AGE accumulation and binding to the receptor 
for advanced glycation end products (RAGE) [147-148] 6. RAGE activation trigger mitogen-
activated protein (MAP) kinase signaling cascade which leads to the activation of NF-kB [149]. 
RAGE promotes the expression of proinflammatory genes including TNF-α, IL-1β, IL-6, and 
reactive oxygen species [150], which results in a vicious cycle of chronic inflammation and bone 
resorption [151]. AGE-mediated activation of RAGE stimulates osteoclasts, which is involved in 
                                                     
6 The author acknowledges the assistance of Dr. Yeon-Ho Cheung in revising this paragraph. 
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diabetic bone loss [152-154]. On the other hand, in vitro resorption assay show that AGEs alter 
the structural integrity of bone matrix proteins and inhibit osteoclastogenesis, resulting in 
decreased osteoclastic bone resorption [155]. RAGE signaling also induces osteoblast apoptosis 
via the MAP kinase and cytosolic apoptotic pathways [156] and limits the proliferation of 
mesenchymal stem cells and differentiation into osteoblasts [157]. The endogenous secretory 
receptor for advanced glycation end products (esRAGE), which blocks RAGE, has been 
demonstrated to be clinically associated with lower risk of fracture [158].  
Importantly, the Wnt signaling pathway is also disrupted by DM. Wnt signaling regulates 
bone metabolism by increasing proliferation and differentiation of osteoprogenitor cells and 
decreases osteoblast apoptosis [159].  Osteocytes are major regulators of the normal balance 
between osteocytes and osteoclasts, and release molecular regulators including sclerostin, a potent 
Wnt inhibitor. Sclerostin suppress bone formation through binds osteoblast surface receptors and 
inhibits the Wnt/-catenin pathway via downstream effects [160]. Sclerostin is upregulated in 
diabetes, due to the effect of hyperglycemia and AGEs on osteocytes [161-164]. Increased 
sclerostin levels have been demonstrated in both T1DM (1.18-fold) and T2DM (1.3-fold) [161-
163]. Furthermore, a 2013 study demonstrated that sclerostin levels in patients with T2DM have 
been directly associated with increased fracture risk [165]. Sclerostin has also been implicated as 
a factor contributing to insulin resistance in addition to its role abnormal bone biology [161,166].  
 
Clinical management of diabetic patients to optimize bone health and reduce fracture risk 
The following sub-section will discuss current evidence regarding management of diabetic 
patients with a focus on musculoskeletal health.  
Lifestyle alterations and vitamin supplementation 
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 Considering the increased fracture risk among patients with T1DM and T1DM, bone 
health should be optimized for all diabetics. Diabetic patients, especially post-menopausal 
women and older men who are already at risk for osteoporosis, should be provided vitamin D 
and calcium supplementation. In addition to being standard of care for osteoporosis, vitamin D 
supplementation has been shown to decrease symptoms of diabetic neuropathy [167-168]. 
Weight bearing exercise should be encouraged for all diabetic patients regardless of age, in order 
to improve bone health in addition to improving insulin sensitivity. Fall risk assessment should 
be considered, especially among elderly diabetic patients. Regular eye exams, which can reduce 
the risk of visual impairment and therefore reduce fracture risk, should also be standard of care 
among diabetic patients [169]. 
Osteoporosis and Antiresorptive Therapy 
Diabetic patients who are diagnosed with osteoporosis should be given standard anti-
osteoporotic therapies as non-diabetics would receive. There is strong evidence showing 
bisphosphonates and raloxifene are as effective in diabetic compared to non-diabetic patients with 
osteoporosis in clinical trials and retrospective studies [170-173]. Animal models have also 
demonstrated the efficacy of bisphosphonates and SERMs in treating bone loss in the context of 
diabetes and osteoporosis [174]. 
Glycemic Control 
HgA1C targets may vary patient to patient in the management of T2 DM, while intensive 
glycemic control is standard of care in T1DM [175]. While poor glycemic control has been 
associated with increased fracture risk in T1DM [176-177], several studies state that there is 
little, if any, correlation with glycemic control in T2DM [176]. According to the ACCORD 
randomized trial, over 7,000 older adults with T2DM randomized to intensive or standard 
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glycemic control groups (median A1C 6.4 and 7.5%, respectively), had no difference in in 
fracture and fall outcomes, with an average of 1.3-year follow-up [178]. Patients with T2DM 
should be managed with at least standard glycemic control to reduce the long-term risk of 
microvascular complications and promote bone health.  
 
 
VIII. Diabetic fracture healing and the need for new treatment approaches  
 
Mechanisms of impaired fracture healing in diabetes 
In addition to an increased risk of fracture, diabetic patients’ bone healing is impaired 
(figure 10), with a higher rate of delayed union and nonunion than nondiabetic patients [123,179]. 
Normal fracture healing is a process dependent on complex interactions of cells and signaling 
molecules, with stability a requirement, as discussed previously in this introduction (figure 5).  
In diabetes, fracture healing is impaired due to decreased fracture stability, altered bone 
metabolism, and an abnormal inflammatory response (figure 10). Stability is at risk, as comorbid 
obesity and abnormal joint loading can reduce stability of the diabetic fracture site, especially 
among lower extremity fractures.  Diabetic peripheral neuropathy may also contribute to poor 
protective sensation following injury and physiologically inappropriate weight bearing.  
Diabetes is marked by increased adipogenesis that leads mesenchymal stem cells to 
preferentially differentiate into adipocytes rather than osteocytes [123,180]. The increased fatty 




Figure 10: Mechanisms of impaired fracture healing in diabetes mellitus.  
Fracture healing is marked by the inflammatory, soft callus, hard callus, and remodeling phases. 
Endochondral ossification facilitates this process. Diabetes disrupts multiple steps of this process. 
Global factors such as poor vascular supply, peripheral neuropathy, obesity, and abnormal joint 
loading affect multiple steps of the process and may decrease fracture stability. Decreased growth 
factor production, including VEGF, BMP2, TGF- β, and PDGF limit angiogenesis and cellular 
proliferation. Increased inflammation, mediated by TNF-⍺, leads to chondrocyte apoptosis and 
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decreased callus size. The number of mesenchymal precursor cells (MPC) is decreased, and MPCs 
demonstrate preferential adipogenesis in diabetes. Remodeling is impaired due to altered bone 
biology, including AGE-induced reduction in osteoblast activity and increased sclerostin 
production. Apop – apoptosis, MPC – mesenchymal precursor cell, Ages – Advanced glycation 
end products. 
 
A rich blood supply is also necessary to facilitate fracture healing. The negative effects of 
diabetes on the microvasculature cannot be overlooked, as the hallmark of end-stage organ damage 
in diabetes is microvascular compromise [115]. Insulin resistance in T2DM is directly related to 
microvascular complications [181], and microvascular changes are also seen early in children and 
adolescents with T1DM [182]. Vascular calcification and smooth muscle cell apoptosis underlie 
diabetic vascular disease, and in vitro studies have demonstrated the significance of AGEs and 
RAGEs in these processes [183-184]. The diminished blood supply impedes the perfusion and 
distribution of important nutrients that encourage fracture healing [185]. 
Overexpression of TNF-α, an inflammatory mediator, is an often-reported cause of 
impaired diabetic fracture healing [186-187]7. TNF-α triggers chondrocytes apoptosis by 
upregulating the expression of apoptotic genes and reduces proliferation of mesenchymal stem 
cells through activation of FOXO1 [188-192]. TNF-α mRNA levels were 3.7-fold and osteoclast 
numbers were 2.5-fold higher in the diabetic fracture than the normoglycemic animals, leading to 
premature resorption of cartilage. Furthermore, TNF-α contributes to reduced angiogenesis and 
VEGFA expression in endochondral bone formation. Inhibition of TNF-α or treatment of insulin 
rescued the negative effect of diabetes on cartilage loss, increased osteoclastogenesis and impaired 
                                                     
7 This and the following paragraph were co-written with Yeon-Ho Cheung, PhD. 
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angiogenesis [190-192]. TNF-α also contributes to reduced angiogenesis and VEGFA expression 
in endochondral bone formation. These negative effects of TNF-α ultimately lead to a decrease in 
callus size, delayed endochondral ossification, and bone formation. In animal models of DM, 
inhibition of TNF-α or treatment with insulin rescued the negative effect of diabetes on cartilage 
loss [179,191].  
Altered expression patterns of other chemokines and other inflammatory mediators in DM 
have been reported. These include bone morphogenic protein – 2 (BMP2), vascular endothelial 
growth factor (VEGF), platelet derived growth factor (PDGF), transforming growth factor beta - 
1 (TGF-Beta1), Monocyte chemotactic protein (MCP) 1, and chemokine c-x-c motif ligand -13 
(CXCL 13) [193-196]. Important transcription factors like core binding factor alpha 1/runt related 
transcription factor 2 (Cbfa1/RUNX2) and distal-less homeobox 5 (Dlx5) are also decreased 
[117,180].  
 
Management of Diabetic Fracture 
Diabetes leads to a high risk of complications following fracture including nonunion, 
malunion, infection, and poor wound healing [119,197-198]. Delayed fracture healing and 
nonunion are important orthopaedic problems, and this patient population often requires more 
complex treatment and management than non-diabetic patients [199-200]. Unfortunately, most 
interventions to improve fracture healing lack strong, high-quality evidence among normal and 
diabetic patients. This section outlines potential strategies for enhancing diabetic fracture healing, 
with glycemic control having the most evidence for clinical practice. Table 1 summarizes these 
strategies. Future research for experimental interventions is needed, and this is the impetus of a 




Table 1: Grades of recommendation for proposed therapies to improve fracture healing in 
diabetes. While several interventions have been proposed to improve diabetic fracture healing, 
most have little to no quality evidence to support them. A=good, level 1 studies with consistent 
findings; B= fair, level II or III studies with consistent finding; C=conflicting or poor-quality 
evidence (level IV or V studies); I = investigational/animal studies only. 
 
Glycemic Control 
Poor glycemic control has been shown to be a significant predictive factor for contributing 
to poor fracture healing. Clinical studies have demonstrated that hemoglobin A1c levels A1C  
6.5% were correlated with poorer radiographic outcomes and increased risk of complications and 
revision [201]. Studies in animal models of type I and type II diabetic fractures demonstrate 
significant improvement in biomechanical properties and bone formation between diabetic rats 
treated with insulin to those untreated [202-205]. The anabolic effect of local insulin is facilitated 
by increased osteogenesis, angiogenesis, and callus formation, and suggests insulin’s direct, 
beneficial effect on fracture healing in addition to contributing to glycemic control [206]. It should 
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be noted that there is little prospective clinical data on whether improving glycemic control at the 
time of fracture can improve fracture healing in long-standing diabetes. Nevertheless, glycemic 
control should be the cornerstone of management for all diabetic patients.  
Furthermore, glycemic control has been shown to reduce infection risk in both diabetic and 
non-diabetic patients. Several randomized control trials have demonstrated that perioperative 
glycemic control reduces surgical site infection rates [207-211]. Although various protocols have 
been used, these trials have maintained patients with target random blood glucose levels less than 
150 mg/dl, using subcutaneous regular insulin or regular insulin infusion. Retrospective studies 
have identified perioperative glucose control to be predictive of increased surgical site infection 
risk in the orthopaedic setting [212]. HbA1c also correlates with surgical infection risk [212], with 
one study demonstrated that for every 1% HbA1c increase, the odds of surgical infection increased 
by a factor of 1.59 (95% CI 1.26-1.99) [213]. Currently, however, there is no consensus on the 
target preoperative HbA1c levels among diabetic patients for preventing surgical site infection. 
Teriparatide and Parathyroid Hormone 
Teriparatide is a peptide comprised of the active portion of parathyroid hormone (PTH). 
PTH is a regulator of calcium and phosphate homeostasis. Teriparatide acts as an anabolic agent 
by stimulating pre-osteoblasts to differentiate and proliferate. Conditions of chronically-elevated 
levels of PTH are associated with hypercalcemia, bone resorption, and phosphate wasting due to 
upregulated osteoclast activation in bone and PTH activity on the kidney (Figure 11). Intermittent 
PTH exposure, however, has selective anabolic properties without excessive osteoclast activation. 
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Figure 11. Mechanisms of hypercalcemia and bone destruction in chronic 
hyperparathyroidism.8 
 
Although not first-line therapy for osteoporosis, teriparatide has been shown to reduce the risk of 
vertebral and nonvertebral fractures and increase BMD in postmenopausal women in randomized, 
clinical trials [214-215]. Teriparatide administration has also been demonstrated to accelerate 
fracture healing in postmenopausal women in some clinical trials [216-217], whereas others have 
showed no benefit [218]. Non-diabetic animal models have demonstrated improved fracture 
healing with teriparatide [219]. However, clinical evidence of teriparatide use among diabetic 
patients is lacking. Animal studies evaluating local and intermittent systemic parathyroid hormone 
administration in diabetic models have shown an improvement in the fracture healing response 
                                                     
8 Figure and drawings prepared by the author for Students Helping Students lecture series: “Calcium Homeostasis 
and Parathyroid Hormone,” Yale School of Medicine, 6/6/2018. 
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[205,220-221]. In addition to improving fracture healing, intermittent teriparatide therapy has also 
been shown to partially reverse bone mineralization and trabecular defects in T2DM animal 
models without influencing blood glucose control. However, the benefits of intermittent 
teriparatide were greater in non-diabetic animals compared to the T2DM phenotype, suggesting 
relative resistance to PTH in diabetes [221].  
Bone Stimulation 
Bone stimulation exposes bone to electrical, electromagnetic, or ultrasound energy to 
accelerate fracture healing [222]. Evidence is mixed as to whether these strategies improve union 
in operatively and non-operatively managed fractures in non-diabetic patients [223-226]. Data is 
especially lacking for use of bone stimulation in the diabetic population. Small, prospective studies 
have demonstrated potential benefit among diabetic patients in foot and ankle surgery [227] and 
treatment of Charcot foot [228], and studies in diabetic animal models demonstrated improved 
bone anabolism under surgical implant and bone defect conditions [229-230].  
Experimental approaches 
Other approaches to improving fracture healing have been investigated and may become 
more prevalent in the future management of diabetic fractures as more clinical evidence is 
gathered. Studies in animals and humans have demonstrated that antibodies against sclerostin 
decrease bone resorption and increase new bone formation in nondiabetic (26% at LV and 17% at 
femur‐ tibia) [231-232] and diabetic conditions [233]. There is evidence demonstrating that local 
insulin therapy improves fracture healing and bone regeneration in non-diabetic [234-235 and 
diabetic [206] animal models. Direct administration of the deficient factors like BMP, CXCL13, 
human platelet-derived growth factor and recombinant human bone morphogenic protein-2 have 
been shown to improve bone healing in in vitro diabetic animal models [236-239. Another 
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approach has been the inhibition of factors like tumor necrosis factor alpha, which can enhance 
MSC numbers and prevent MSC apoptosis [189]. 
 
IX. The role of murine models to study fracture healing and musculoskeletal disease 
There are many biological systems in which fracture healing has been studied, including 
biopsy sampling of human specimens; in vitro studies including progenitor cells, immune cells, 
and osteoblasts; small animal models, including mice and rats; and larger animal models such as 
rabbits, dogs, and horses. All have advantages and disadvantages.  
Mice are the most common small animal model in all biomedical research. They are readily 
obtained, breed and mature quickly, and are relatively cheap to house, feed, and maintain owing 
to their small size. Mice also are available in a huge array of strains – the Jackson Laboratory, one 
of the main providers of laboratory mice, report more than 7,000 different mouse strains available 
for purchase. Certain strain-dependent characteristics are desirable in bone and fracture healing 
studies are necessary to model musculoskeletal conditions in certain diseases. For example, 
nude/athymic mice, which lack T cells, are widely used in studies modeling metastatic bone 
cancer, in which tumor cells are directly implanted into bone. A variety of mouse strains with 
genetically-acquired diabetes, such as DB/DB (leptin receptor deficient) and Tallyho (multigenic) 
strains, have been used to study diabetic bone disease. Additionally, transgenic and knockout mice 
can be obtained with relative ease for studying specific molecular pathways that may affect fracture 




Purpose and Specific Aims 
The overarching purpose of this dissertation is to use animal models of inflammatory 
fracture healing, including infection and diabetes, to identify new therapeutic strategies for 
promoting bone healing. Although the aims of this dissertation are broad, the ultimate purpose is 
to provide a basis of animal studies on which future clinical studies can be undertaken to implement 
these strategies to improve patient outcomes. 
Throughout the course of the work on these investigations into inflammatory fracture 
healing, more questions have arisen than have been answered. Efforts have been undertaken to 
begin to attempt to address them, which have been included within this dissertation but are by no 
means complete. A description of ongoing investigation and plans for future investigation are 
provided at the conclusion of this work 
Primary research questions of this project are: 
1) Can a locally-applied, antibiotic-containing hydrogel reduce bacterial load and improve 
fracture healing in the setting of MRSA infected fracture? 
2) What cellular and molecular changes occur that inhibit fracture healing in the setting 
of Staphylococcal infection? 
3) Can a high-fat, high-sugar diet be used to model diabetic fracture healing and the 
propensity for infection in mice? 
4) Can locally-applied teriparatide, via hydrogel delivery, improve fracture healing in 
diabetic mice? How does it compare to systemic, intermittent administration? 
5) Can systemically-delivered teriparatide improve fracture healing in cases of acute post-
traumatic infection? 
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6) What accounts for the observation that fracture healing in diabetic mice is improved 









The following section details the methods used throughout this dissertation. Since many of the 
methods (animal care, surgical model, histology preparation, etc.) are used among various 
components of this dissertation, the overall experimental designs of each component of the 
project are presented first, followed by detailed methods. 
 
Summary of Experimental Designs 
1) Local antibiotic delivery to reduce bacterial load and improve fracture healing in a 
MRSA-infected open tibia fracture mouse model. 
The overall experimental design is given in Figure 12. Normal c57 mice age 10-12 weeks 
were subjected to open tibia fracture surgery. Mice in the infection group were directly inoculated 
with MRSA at the time of surgery. Hydrogel treatment containing PBS only (control group) or 
rifampin were applied after a 10-minute incubation period during the surgical procedure. Mice 
were sacrificed at 3, 14, and 28 days. Colony-forming unit analysis was obtained after 3 days. 
Histology was performed at days 14 and 28. Radiographic analysis including x-ray and micro-
computed tomography (micro-CT) were performed at day 28. Blood was collected for CBC and 
serum analysis at 7, 14, and 28 days. 
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Figure 12. Experimental design summary for MRSA infection/hydrogel experiment.9  
  
2) Local and systemic teriparatide to improve fracture healing in diabetic mice. 
Mice were kept on a high-fat, high sugar diet (diabetic model) or lean diet (control) for 6 months, 
with body weight, glucose tolerance test, and fasting blood glucose measured at various 
timepoints. Mice underwent sterile fracture surgery. Mice in the local treatment group had 
teriparatide-containing hydrogel applied directly to the fracture site. Mice were sacrificed at 14 
and 28 days. Primary analysis included x-ray and micro-CT analysis at 28 days following surgery. 
Histology was obtained after 14 days; histologic results are pending at the time of dissertation 
submission.    
3) Diabetic fracture healing under infected conditions: the effect of antibiotics and 
systemic teriparatide in a MRSA-infected, open tibia fracture mouse model.  
Diabetic and control mice were used. Mice underwent sterile fracture surgery and those in the 
infection groups were inoculated with MRSA at the time of surgery. Mice were treated with 
                                                     
9 The author acknowledges the assistance of Dr. Hyuk-Kwon Kwon in preparing this figure. 
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systemic vancomycin/rifampin combination (3 days), and systemic vancomycin/rifampin 
combination (3 days) plus teriparatide (once daily for 5 days per week over 28 days). Mice 
were sacrificed at 28 days. Primary analysis included x-ray and micro-CT analysis at 28 days 




Experiments were approved by the Yale University School of Medicine Institutional 
Animal Care and Use Committee. Male C57BL/6J mice aged 10-12 weeks were purchased from 
Jackson Laboratories (Bar Harbor, ME, USA) for use in infection/rifampin hydrogel experiment. 
Male C57BL/6J mice aged 4 weeks were purchased from Jackson Laboratories Animals for the 
diabetic model. Animals were housed at 22 ± 3°C on a 12-hour light/dark cycle in ventilated cages 
and were given food and water ad libitum. The author acknowledges the support from the Yale 
Animal Resource Center, especially Mark Chernyak, for their dedication to our animals’ well-
being.  
 
Type 2 Diabetic Mouse Model and Metabolic Testing 
Male C57BL/6J mice aged 4 weeks were purchased from Jackson Laboratories (Bar 
Harbor, ME, USA). Animals were housed at 22 ± 3°C on a 12-hour light/dark cycle in ventilated 
cages and were given food and water ad libitum. Type 2 diabetes was modeled by providing mice 
                                                     
10 This work required efforts from a large investigational team in the Lee lab and the Department of Orthopaedics 
and Rehabilitation. Experiments were carried out by the author, unless noted in the text. The author would like to 
acknowledge Dr. Kwon and Dr. Back for their teaching in nearly all methods used in this investigation and for 
helping to facilitate all experiments. The author would like to thank Dr. Lee for providing resources and financial 
support for this work. The author would like to acknowledge Kareme Alder, Inkyu Lee, and Saelim Lee for their 
assistance in carrying out animal experiments and their help as mouse surgery assistants.  
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with a high fat, high sugar diet (40% fat by weight with added sucrose), mimicking a Western diet. 
Wild-type, age-matched controls were provided standard chow. Mice underwent glucose tolerance 
testing after 3 months on the HFHS diet. Age-matched Tallyho mice were tested as positive 
controls. Mice were fasted overnight before the tolerance test. Baseline fasting blood glucose 
levels were measured with a commercially available glucometer using blood collected from the 
tail vein (maximum reading 600 mg/dL). During tail vein collection, efforts were made to 
minimize mouse stress, and anesthesia was not used. An intraperitoneal injection of 20% glucose 
solution was given, with a total glucose load of 2g/kg. Blood glucose levels were measured at 15, 
30, 60, and 120 minutes following injection. Fasting blood glucose levels were measured at 6 
months. Animals underwent surgery at 7-8 months. The author performed all metabolic testing. 
 
Hydrogel Preparation 
A 2% weight/volume collagen-based hydrogel was made using the HyStem™ hydrogel 
system (ESI BIO, Alameda, CA, USA) by reconstituting and combining Glycosil and Extralink-
Lite per manufacturer’s instructions, at a 2:1 ratio. 10 µL of gel was allowed to polymerize for 20 
minutes. An equal volume of phosphate buffered saline (PBS) containing rifampin of doses 0 µg 
(sterile fracture and MRSA infection), 60 µg (low-dose), and 300 µg (high dose) were added to 
the hydrogel. For the teriparatide hydrogel preparation, a dose of 40 µg/kg was loaded into the 
hydrogel in a 10 µL solution. 
 
Surgical Open Fracture Model 
The tibia fracture surgical procedure was based on previous fracture healing studies and 
were developed by the author for the purpose of these experiments [20-21]. The author (SC) 
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performed all surgeries. Anesthesia was achieved with ketamine (50 mg/kg) and xylazine (5 
mg/kg). Depth was assessed by pedal withdrawal. Buprenorphine (0.1 mg/kg intraperitoneal) and 
bupivacaine (4 mg/kg subcutaneous) were given pre-emptively. Hair of the right leg was removed 
with depilatory cream and skin was disinfected with povidone-iodine and alcohol. An incision was 
made over the right tibia. The patella was lateralized and a 25-gauge needle was used to pre-drill 
a hole in the cortical bone of the proximal tibia shaft. A scalpel was used to create a transverse, 
non-comminuted, mid-shaft fracture just distal to the tibial prominence (figure 13). The fracture 
was stabilized with a 0.35mm insect pin inserted at the proximal tibia. Care was used to minimize 
bleeding and surrounding tissue damage. 5 L of PBS containing 1 × 106 CFU MRSA (USA 300) 
was applied to the fracture site. The author acknowledges Dr. Kwon for handling and preparing 
the bacteria sample. An incubation period of 10 minutes was allowed. The fracture site was dried 
of excess moisture with sterile gauze, and hydrogel was then applied. The wound was closed using 
sutures.  
Mice in systemic rifampin therapy groups were given 25 mg/kg subcutaneous injections, 
based on previous mouse studies investigating Staphylococcal implant and bone infection [251-
253]. Mice were treated over a three-day period as per clinical guidelines [254-255], with one 
injection immediately following surgery and then 24 and 48 hours later.  
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Figure 13. Mouse MRSA-infected, open tibia fracture model. (a.) Skeletonized mouse lower 
extremity, demonstrating bony anatomy including the fracture site, tibial prominence, patella, 
fibula, and ankle joint. Skeleton was prepared by the author. Flesh was cleared with dermestid 
beetles and bones were bleached by soaking in 3% hydrogen peroxide for 12 hours. (b.) An 
incision was made over the anterior right tibia, and 0.35mm stainless steel insect pin was pre-
inserted into the medullary canal. A transverse mid-shaft fracture was made and stabilized by 
advancing the pin. MRSA (USA 300) was directly applied to the fracture site and allowed to 
penetrate tissue for 10 minutes before applying hydrogel and closing with sutures. (c.) Post-





For mice receiving systemic intermittent teriparatide treatment, a subcutaneous injection 
containing 40 µg/kg was given immediately following surgery 5 days per week over 28 days, for 
a total of 20 injections. 
Blood was obtained retro-orbitally at 7, 14, and 21 days. Complete blood counts were 
measured using VetScan HM5 (Abaxis, Union City, CA, USA).  
Mice were euthanized via cardiopuncture under anesthesia at post-surgery day 3, 14, and 
28. The author acknowledges Dr. Kwon, Inkyu Lee, Kareme Alder, and Saelim Lee for their 
assistance with surgical procedures and animal harvesting and specimen collection.  
 
Bacterial Colony-Forming Unit Analysis 
Tibiae were harvested in a sterile fashion after 3 days. Intramedullary pins were removed, 
placed in 1.00 mL PBS, and vortexed at medium speed for 10 minutes. 100uL of the resulting 
solution was plated onto MRSA-specific Meuller-Hinton agar (Sigma-Aldrich, St. Louis, MO, 
USA) containing oxycyclin (6 µg/mL; Sigma-Aldrich Co.). Tissue samples containing bone and 
soft tissue from the fracture site were isolated, manually homogenized, then incubated in 1.00 mL 
0.25% collagenase solution (Stem Cell Technologies, Vancouver, BC, Canada) for 1 hour at 37C.  
1 × 105 cells were plated and allowed to incubate for 36-48 hours at 32C. Plates were imaged 
with ChemiDoc Touch (Bio Rad, Hercules, CA, USA). Colonies were counted using ImageJ 
software (NIH, Bethesda, MD, USA). The author acknowledges Hyuk-Kwon Kwon for assistance 
in carrying out these experiments. 
 
Radiographic and Histologic Analysis 
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Anterior-posterior (AP) and lateral radiographs were obtained by the author using In-Vivo 
Multispectral FX Pro (Bruker, Madison, WI, USA) after 28 days. Healing was assessed by the 
radiographic union scale in tibia fractures score (RUST score, Table 1) by two individual 
researchers (The Author, Kwon) [256-257]. A score of 10 was considered radiographic union.  
Tissues were randomly assigned to histologic analysis or μCT, with additional histology tissues 
harvested at 14 days.  
 
 




Histology tissues were fixed in 10% neutral buffered formalin and decalcified in 0.5 M 
solution ethylenediaminetetraacetic acid, pH 8.0 (American Bio, Natick, MA, USA) for at least 
days. Intramedullary pins were removed. Tissues were dehydrated with graded alcohols, cleared 
with xylene, and paraffinized using the Tissue Tek VIP tissue processor (Sakura Finetek, Torrance, 
CA, USA). The author acknowledges the assistance of Nancy Troiano, MS, and the Yale 
Orthopaedics Histology and Histomorphology Laboratory for their assistance in preparing and 
staining specimen slides. Tissues were cut into sections 5 microns thick, mounted onto slides, and 
stained with Gram, hematoxylin and eosin, and Safranin O stains. Histology images were obtained 
using Cytation 5 (BioTek Instruments, Winooski, VT USA).  
Whole tibiae were used for µCT analysis of cancellous bone inside the callus with the 
Scanco µCT 50 (Scanco Medical, Brüttisellen, Switzerland) system [258]. 10µm voxel size, 
55KVp, 0.36 degrees rotation step (180 degrees angular range) and a 1000 ms exposure per view 
were used for the scans which were performed in 70% alcohol. The Scanco µCT software (HP, 
DECwindows Motif 1.6) was used for 3D reconstruction and viewing of images. After 3D 
reconstruction, volumes were segmented using a global threshold of 400 mg HA /mm³.  Tissue (in 
this case Bone) mineral density (TMD), directly measured bone volume fraction (BV/TV), 
connectivity density, surface to volume ratio (BS/BV), thickness (Tb.Th), number (Tb.N) and 
separation (Tb.Sp) were calculated for the trabecular bone formed inside the callus. Imaging and 
analysis were performed by the bone imaging core at Columbia University. 
 
Immunohistochemistry 
Immunohistochemistry was conducted by using Rabbit-specific HRP/DAB Detection IHC 
Detection Kit – Micro-polymer (Abcam, ab236469). Slides were first deparaffinized by washing 
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three times in Xylene (Fisher chemical, Belgium) for five minutes and in graded alcohol (Decon 
Laboratories Inc, Pittsburg, PA) concentrations — 100%, 95%, 70% — for five minutes each. 
Antigen unmasking was performed utilizing a heated 0.1 M sodium citrate solution (J. T. Baker, 
Phillipsburg, NJ) for ten minutes. Following antigen unmasking, slides were washed in 1x TBST 
(American Bio, Canton, MA) three times for five minutes each. Hydrogen Peroxide Blocking was 
performed for 30 minutes using the IHC detection kit at room temperature. Slides were then 
rewashed in 1 x TBST solution three times five minutes each. Sections were then incubated with 
protein block from the kit for 30 minutes and then incubated in the chosen primary antibody at a 
concentration of 1:200 overnight at 4° C. Primary antibodies used included: IL1b: ab9722, Pp65: 
ab86299, Sox9: ab185966, Runx2: BNP1-77461. 
After overnight incubation, slides were washed in 1 x TBST three times for five minutes 
each. Then, immunohistochemistry was performed by applying Goat Anti-Rabbit HRP Conjugate 
for 30 minutes along with 1 x TBST washing after. Samples were then visualized by 
diaminobenzidine (DAB) substrate. DAB-visualized sections were then counterstained with 
Harris’ Hematoxylin, 1% acid alcohol, and ammonium water. Following counterstaining, the 
tissues were rehydrated in 100 % Ethanol three times five minutes and Xylene three times five 
minutes before adding the slide cover.  The author acknowledges Inkyu Lee for performing 
immunohistochemistry staining procedures for these experiments. 
Slide images were captured using a Gen5 3.02 (BioTek CYTATION5 image reader); 




Following µCT, samples were placed in PBS before undergoing biomechanical testing. 
Flexural rigidity was evaluated using a nondestructive 3‐ point bending test. Each sample was 
loaded to a maximum force of 1.5 N and flexural rigidity (EI) was calculated from the slope (k) of 
the linear region of the load–deflection curve. Since the callus was not always located in the middle 
of the supports, the distances between the load vector and the proximal (a) and distal (b) supports 
were considered for calculating (N mm2). 
  The proximal and distal ends of the bone were then potted in brass cylinders. Femora were 
subjected to torsion at 1°/s. The gage length was measured for each specimen. Torque and 
displacement data were recorded at a rate of 20 Hz. Maximum torque, torsional rigidity, the twist 
to failure and twist to max load (units: radians normalized by gage length), and toughness were 
calculated using a custom routine in LABVIEW (National Instruments, Austin, TX, USA). 
Torsional rigidity was defined as the slope of the initial portion of the torque-twist curve, where 
twist was normalized by gage length, and toughness was defined as the area beneath the curve up 
until the maximum torque was reached. The author acknowledges Steven Tommasini, PhD, for 
carrying out these biomechanical tests.  
 
Statistics  
All analyses were performed by the author with Prism8 (GraphPad Software, La Jolla, CA, 
USA). Means and standard deviation (SD) were calculated for all data sets. Differences among 
groups were compared with ANOVA with multiple comparisons, to assess fracture healing 
parameters (micro-CT, RUST score, torsional strength) among treatment condition groups. For 
glucose tolerance testing, geometric area under the curve (AUC) was calculated for each group to 
compare glucose tolerance. Differences between diabetic and wild-type groups for blood glucose 
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testing, glucose tolerance testing, body weight, and uninterrupted fracture healing parameters were 






1. Rifampin-loaded hydrogels decrease bacterial load and improve fracture healing in a 
MRSA-infected open fracture model. 
96 mice were used in this study. Two died spontaneously within 24 hours after surgery. No 
signs of systemic infection were observed. No animals were euthanized prematurely. On CBC 
analysis, MRSA infection trended to increased total and percent neutrophil count, as well as total 
monocyte count. However, no significant differences among groups were observed, including 
sterile fracture versus MRSA infection. 
Untreated MRSA infection resulted in mean tissue CFU count of 6296 colonies (figure 
14). Low-dose rifampin hydrogel reduced this count to 3149 (p=0.022). High-dose rifampin 
hydrogel recovered a mean of 2 CFU (p<0.0001) and systemic rifampin 0.4 CFU (p<0.0001). 
Untreated MRSA infection resulted in mean detection from implant of 1657 CFU, low-dose 
rifampin hydrogel of 356 CFU (p=0.14), high-dose rifampin hydrogel of 0 CFU (p<0.041) and 
systemic rifampin 0 CFU (p<0.041).  
Among sterile fractures, radiographic union was achieved in 88% of cases (mean RUST 
11; Figure 15). Among untreated infections, zero samples achieved union (mean RUST 6, 
p<0.0001; Figure 3). A statistically significant improvement of mean rust score was identified 
between MRSA infection and the high-dose local rifampin group (mean 8.7, p<0.024). Systemic 
rifampin and combined systemic/hydrogel treatments resulted in recovered fracture healing (mean 
10, p=0.0005; mean 10.7, p<0.0001, respectively). No significant differences were observed 
among the sterile fracture, high-dose hydrogel, or systemic treatment groups. On tissue harvest at 




Figure 14. Bacterial colony forming unit analysis of fracture site tissue and implants after 3 
days11. Following tissue harvest, implants were sterily removed, vortexed in an aliquot of 1 mL 
PBS for 10 minutes. 100 uL of the resulting solution was plated onto MRSA-specific medium. 
Fracture site tissues were isolated, homogenized, and digested with collagenase. 1x105 cells were 
plated onto MRSA-specific medium. Plates were allowed to incubate for 36-40 hours. 
Representative images from each treatment condition are shown in (a) for tissues and (b) for 
                                                     
11 The author acknowledges Dr. Kwon for assistance in obtaining the cell culture plate images used in this figure. 
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implants. Quantitative analysis of bacterial loads is shown in (c) for tissues and (b) for implants. 
n = 4-5 per group. Mean with 95% CI shown. Differences were assessed by ANOVA with multiple 
comparisons, MRSA infection as control group. *p<0.05, ****p<0.0001, ns p>0.05.  
 
 
Figure 15. Radiographic and gross healing of fracture sites after 28 days. (a) Representative 
lateral (LAT) and antero-posterior (AP) views from each treatment condition are shown. (b) 
RUST scores were calculated, n =6-8 per group. Mean with 95% CI shown. Differences were 
assessed ANOVA with multiple comparison test. *p<0.05, ***p<0.001, ****p<0.0001, ns 
p>0.05. (c) Photographs of gross sterile and infected fracture sites after 28 days. Infected cases 
were obvious, with gross pus at the fracture site and inflammation at the knee joint.  
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 μCT demonstrated a well-healed callus among sterile fractures and samples demonstrating 
radiographic union (figure 16a). Infected fracture sites were marked by nonunion and 
demonstrated involucrum, with “bone within bone” appearance typical of osteomyelitis [259].  A 
significant increase in bone volume at the fracture site was calculated between sterile controls and 
MRSA infection (4.52 mm3 vs 13.77 mm3, p=0.034). Bone volume, total volume, bone density, 
and trabecular thickness were all significantly decreased with systemic rifampin therapy compared 
to untreated MRSA infection (p values <0.05, figure 16b). 
 
Figure 16. µCT images and analysis of fracture sites after 28 days. (a) Select 3-dimmensional 
reconstructions of healed tibiae, with bone surface (BS) and cut surface (CS) views. (b) Analysis 
of callus area total volume (TV), bone volume (BV), bone density (BV/TV), trabecular thickness 
(Tb.Th), bone surface/bone volume (BS/BV). n =4 per group. Mean with 95% CI, n = 3-4 samples 
per group. Differences assessed by ANOVA with multiple comparisons. *p<0.05, **p<0.01. 
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Biomechanical strength testing between sterile fracture and MRSA infection samples after 
28 days demonstrated significantly reduced flexural rigidity (mean 973.6 N mm2 to 248.4 N mm2, 
p<0.05) and significantly reduced maximum torque (21.2 N mm to 4.8 N mm, p<0.01, figure 17). 
Nonsignificant trends of increased biomechanical properties among local and systemic treatment 
groups compared to MRSA infection were observed for parameters including flexural rigidity, 
torsional rigidity, maximum torque, and toughness to maximum torque.  
 
Figure 17. Biomechanical strength testing of fractured tibiae after 28 days. Tibiae were 
isolated and underwent biomechanical strength testing. Flexural rigidity, torsional rigidity, max 
torque, and toughness to max torque were calculated. MRSA-infected samples showed 
significantly decreased flexural rigidity and max torque compared to sterile controls, and trends 
toward increased biomechanical parameters were observed among treatment groups compared to 
MRSA infection. Mean and 95% CI shown, n = 3-4 samples per group. Differences were assessed 
using ANOVA with multiple comparisons. *p<0.04, *p<0.01. Mean with 95% CI, n = 3-4 samples 
per group. Differences assessed by ANOVA with multiple comparisons. *p<0.05, **p<0.01. 
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On histology, sterile callus areas were well-demarcated and organized (figure 18). Sterile 
fracture samples demonstrate bridging soft callus with chondrocyte proliferation at 2 weeks, with 
soft callus spanning the fracture site. At 28 days, bony bridging and mineralized tissue was 
present.. Cement lines clearly demarcated necrotic and healthy bone. No bacteria were observed 
at the fracture site on Gram stain. 
 
Figure 18. Select histology of sterile and infected fracture sites after 14 and 28 days. Slides 
were stained with hematoxylin and eosin (H&E), safranin O (inlet/magnified view), and Gram 
stain (inlet/magnified view) at 14 and 28 days. Select representative histology samples are shown 
here for clarity. Vertical intramedullary pin tracts are seen in the low-power H&E views at 14 
and 28 days. Sterile fracture cases demonstrated soft, cartilaginous callous at 14 days, and bony 
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callus with remnant cartilage matrix at 28 days. Cartilage matrix is identified as red staining 
area on safranin O. Areas of necrotic bone with empty lacunae (*) abutting healthy bone were 
observed at the sterile callus sites. No bacteria were present on Gram stain. MRSA-infected 
samples demonstrated sequestrum with bone necrosis and bacteria within the lacunar space 
(arrows), and involucrum formation (+). Scant cartilage and dense lymphocytic infiltrate were 
also observed. Histology samples from high-dose hydrogel and systemic therapy groups in which 
infection was eliminated are shown, resembling sterile healing. n = 3-4 per group. 
 
MRSA-infected fractures demonstrate dense lymphocytic infiltrate with scant cartilage 
formation at 2 and 4 weeks, with a disorganized callus area and lack of soft and bony bridging. 
Involucrum was identified in infected cases by14 weeks, with profuse development of mineralized, 
but disorganized, tissue by 4 weeks. Extensive areas of bone necrosis of cortical bone at the 
fracture site were observed, with lacunae empty of osteocyte nuclei. Bone resorption at the fracture 
site was also observed. Gram-positive organisms were observed on Gram stain infiltrating the 
lacunae of cortical bone, as well as within the medullary space, by 4 weeks in infected cases. 
Cases treated with antibiotic therapy, including systemic rifampin and local rifampin, resulted 
in binary morphologic appearance by 14 and 28 weeks, resembling either sterile fracture cases or 
untreated MRSA-infection. Briefly, successfully treated cases demonstrated well-organized 
cartilaginous and bony callus by 14 and 28 weeks, respectively. No differences in morphology 
were observed between cases successfully treated by local or systemic antibiotics. Treated cases 
that did not successfully clear infection (ei, hydrogel antibiotic delivery) were marked by 
lymphocytic infiltration, involucrum formation, and extensive bony necrosis and Gram-positive 





Figure 19. Lacunar colonization of cortical bone by MRSA. Gram stained slide of cortical 
bone adjacent to fracture site with high-power view (inlet, right). Gram positive organisms (dark 
stain) are seen colonizing an area of lacunar bone. Lack of nuclei in lacunae indicate necrotic 
bone, where sequestrum is formed. 
 
 
2. MRSA-infected nonunion is characterized by impaired chondrocyte and osteoblast 
differentiation and maturation and is associated with IL-1 and NF-KB activation. 
 
Failure of chondrocyte proliferation and maturation marked the major morphological change 
observed in MRSA-infected fracture healing compared to sterile controls. In sterile fracture 
healing, abundant soft callus bridged the distal and proximal bone fragments at 14 days. The soft 
callus contained active chondrocytes and abundant cartilage matrix observed via Safranin O stain. 
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On day 28, no active chondrocytes were present, but residual cartilage matrix was observed on 
Safranin O (figure 20).  
The major morphological change in MRSA-infected fracture healing was reduced chondrocyte 
proliferation and maturation. MRSA infection did not preclude chondrocyte proliferation, as 
chondrocytes were observed at days 14 and 28. However, chondrocytes failed to form a soft callus 
bridge between the distal and proximal bone fragments at day 14, and only scant chondrocyte 
populations were observed. Proliferating chondrocytes were observed at the edges of the 
involucrum, and in rare cases distal and proximal involucrum were bridged by chondrocytes. If 
involucrum bridging occurred, it was only observed across one cortex. In contrast to the remnant 
cartilage matrix seen on day 28 in sterile fracture cases, no mature cartilage matrix (matrix without 
active chondrocytes) was present on Safranin O stain in MRSA-infected cases. 
SOX9 and RUNX2 are key transcription factors for differentiation of chondrocytes, and 
RUNX2 is also involved in osteoblast differentiation. Immunohistochemistry performed at 14 days 
demonstrated SOX9 expression in the areas of soft callus in both sterile and MRSA-infected 
controls, however staining was significantly stronger with more positive cells among the sterile 
fracture group. RUNX2 immunostaining demonstrated a similar trend, with abundant RUNX2 
positive cells at the fracture callus at 14 days versus scant cells with weak staining in MRSA-




Figure 20. Safranin O staining demonstrates poor soft callus formation and incomplete 
cartilage maturation in MRSA-infected fracture. Safranin O stain obtained from representative 
sterile fracture and MRSA infection cases (n=6 in each group) after sacrifice at 14 and 28 days. 
Sterile fracture is marked by dense, well-organized bony callus, mature residual cartilage matrix 
(red/purple stain on Safranin O), and lack of bacteria on Gram stain (not shown). MRSA infection 
demonstrates poor callus formation with incomplete bridging. Immature cartilage is identified by 
pink/red stain on Safranin O, with active chondrocytes present that have not undergone the 




Figure 21. Chondrocyte differentiation occurs in MRSA infection, but failed chondrocyte 
maturation is marked by absence of RUNX2 expression. Representative immunohistochemical 
staining (IHC) following sacrifice at 14 days in sterile and MRSA-infected fracture (n=3). Brown 
staining indicates positive cells. Despite reduced chondrocyte population in MRSA infection, IHC 
revealed the presence of active expression of SOX9, a key transcription factor for chondrocyte 
differentiation. Staining for RUNX2, however, demonstrated absent signaling in MRSA infection. 
RUNX2 is a key transcription factor for facilitating chondrocyte differentiation into the 
hypertrophic phase.  
 
Further, immunohistochemistry demonstrates that IL-1B activation was associated with 
decreased chondrocyte proliferation in our MRSA-infected nonunion model (figure 22). 
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Interestingly, chondrocytes at the fracture site stained positive for IL-1B in both sterile and infected 
conditions at 14 days. IL-1B staining was strongly positive in association with the dense, 
leukocytic infiltrate observed in MRSA-infected healing. Positive stains for IL-1B were observed 
at areas of cortical bone resorption as well as the area between involucrum and cortical bone. 
Proliferating chondrocytes in MRSA-infected samples were absent in areas adjacent to IL-1B 
expression. Immunohistochemical staining for p-p65 (activated NF-KB) demonstrated NFKB 
activation in chondrocytes in both sterile fracture healing and MRSA-infected fracture (figure 23). 
 
Figure 22. IL-1 is expressed by chondrocytes in normal fracture healing, but also is highly 
expressed in areas absent of chondrocytes in MRSA infection. Representative 
immunohistochemical staining (IHC) following sacrifice at 14 days in sterile and MRSA-infected 
fracture (n=3). Brown staining indicates positive cells. Chondrocytes positive for IL-1 were 
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identified in both infected and sterile conditions. Densely positive IL-1 staining adjacent to bone 
(arrows) was associated with areas absent of chondrocyte populations.  Involucrum is indicated 
by *. 
 
Figure 23. NFKB is activated in chondrocytes in normal and infected fracture healing. 
Representative immunohistochemical staining (IHC) for p-p65, the activated form of the signaling 
protein NFKB following sacrifice at 14 days in sterile and MRSA-infected fracture (n=3). NFKB 
is a key signaling protein involved in inflammation and non-specific innate immune defense. 
Chondrocytes in both sterile and infected fractures stained positive for p-p65, the activated form 
of NFKB.  
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3. A high-fat, high-sugar diet induces a type 2 diabetic phenotype characterized by obesity, 
impaired glucose metabolism, increased infection burden, and poor fracture healing 
characteristic of type 2 diabetes. 
As discussed in the introduction, the pathogenesis of type 2 diabetes is dependent on several 
factors, but obesity poses the strongest correlation. After 3 months, mice fed a high fat, high sugar 
diet (HFHS) developed on obese phenotype compared to lean-fed controls, with copious 
intraperitoneal fat deposition and gross fat deposits in the liver (figure 24). HFHS mice had a mean 
body weight of 45.1 g (SD 5.6) compared to 28.3 g (SD 2.25) lean-fed controls (p<0.0001, figure 
25). This indicates a 160% increase in mean body weight among the HFHS group. 79 lean-fed 
mice and 105 HFHS were used for experiments in this portion of this study12. 
   
Figure 24. A high-fat, high sugar diet induces obesity in mice. A) Gross appearance of lean-
fed mice and mice fed a high fat, high sugar diet (HFHS) on sacrifice after 6 months. B) 
                                                     
12 Fracture healing and histology results from the second “generation” of this experiment are pending, as noted 
throughout this section. 
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Photograph demonstrating copious intraperitoneal observed in the HFHS mice compared to lean 
controls. C) Normal appearance of gross liver specimen in lean-fed mice, and D) liver with gross 
enlargement and fatty deposition in HFHS mice.   
    
Figure 25. A high-fat, high sugar diet induces obesity in mice by 3 months. 
Mice maintained on a high fat, high sugar diet demonstrated a 160% increase in body weight by 
3 months. Body weights with mean and 95%CI are shown. Difference assessed by unpaired T-test. 
****p<0.0001. 
 
The clinical diagnosis of diabetes can be made with a glucose tolerance test or increased fasting 
glucose. After 3 months on a high-fat, high-sugar diet, mice exhibited impaired glucose tolerance, 
with area under the curve (AUC) of 61,945 mg-min/dL (SD 9,228), compared to 47,128 mg-
min/dL (SD10,862) among lean-fed controls (p<0.0001; figure 26). While there is no standardized 
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cutoff value for diagnosing diabetes among mice, the degree of elevation was similar to the Tallyho 
positive control, which exhibited AUC of 63,465 mg-min/dL (n=3, SD 6,198). After 6 months, 
fasting blood glucose levels were significantly higher in the HFHS mice (mean 171.4 mg/dL, SD 
33.7, n=79) compared to lean controls (mean 129.8 mg/dL, SD 21.6, p<0.0001, n=105, figure 27). 
  
Figure 26. Mice fed a high fat, high sugar diet develop impaired glucose tolerance by 3 
months compared to lean-fed controls. Results of intraperitoneal glucose tolearance test after 3 
months on a high fat, high sugar diet (HFHS) compared with lean (normal age-matched) controls 
and Tallyho mice (positive control). An intraperitoneal injection was given with glucose load 
2g/kg. Blood glucose levels were measured at 15, 30, 60, and 120 minutes following injection. 
Geometric area under the curve (AUC) was calculated to quantify glucose tolerance. HFHS mice 
demonstrated significantly impaired glucose tolerance compared to lean-fed controls, with a 
degree of elevated AUC comparable to Tallyho. Mean and 95%CI are shown. AUC difference 
between HFHS and lean groups assessed by unpaired T test. ****p<0.0001. 
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Figure 27. Pre-operative blood glucose levels are elevated in mice fed a high fat, high sugar 
diet compared to lean-fed controls. Blood glucose levels were measured with a commercially 
available glucometer via tail vein sampling after 6 months. Blood glucose levels with mean and 
95% CI are shown. Difference assessed by unpaired T-test. ****p<0.0001. 
 
 
Diabetes is marked by poor fracture healing, and HFHS mice exhibited reduced radiographic 
fracture healing compared to lean-fed mice. 28 days after fracture, lean-fed mice exhibited a mean 
RUST score of 11 (n=3, SD 1) compared to HFHS fracture sites of 7.5 (n=4 SD 0.58), p<0.002 
(figure 28)13. Micro-CT (n=4 per group) also demonstrated diminished micro-architecture of the 
diabetic fracture sites across all measured parameters (figure 29): bone density (bone 
volume/tissue volume), lean mean  48.8% vs HFHS mean 14.1%, p=0.0051; trabecular number, 
lean 6.4/mm vs HFHS 3.3/mm, p=0.0188; trabecular thickness, lean 0.11 mm vs HFHS 0.054 mm, 
                                                     
13 These sample sizes are small; currently the author is waiting for access to the x-ray machine located in a 
collaborator’s lab to obtain measurements of more samples. Nevertheless, a significant difference was identified in 
RUST score. 
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p=0.0002; trabecular space, lean 0.19 mm vs HFHS 0.33, p=0.03; tissue mineral density, lean 960 
g/cm3 vs HFHS 891.9 g/cm3, p=0.0053; and bone surface/bone volume, lean 29.32 mm2/mm3 vs 
HFHS 54.23 mm2/mm3, p=0.0009.  
  
Figure 28. Mice maintained on a high fat, high sugar diet demonstrate poorer radiographic 
healing scores 28 days after fracture compared to lean-fed mice.  Representative lateral (LAT) 
and antero-posterior (AP) radiographs from tibiae harvested from (A) lean and (B) high fat/high 
sugar fed (HFHS) mice 28 days after sterile fracture. (C) RUST scores demonstrating decreased 
healing among HFHS mice, n =3-4 per group. Mean with 95% CI shown. Differences were 





Figure 29. Micro-CT images and analysis of fracture sites after 28 days reveal impaired 
callus formation in mice fed a high fat, high sugar diet compared to lean-fed controls. (a) 
Representative 3-dimmensional reconstructions of healed tibiae demonstrating lack of bony 
bridging and poor callus formation at the fracture site of mice fed a high fat, high sugar diet 
(HFHS). Quantitative analysis of callus B) bone density (BV/TV), C) trabecular number (Tb.N), 
D) trabecular thickness (Tb.Th), E) trabecular space (Tb.Sp), F) tissue mineral density (TMD), G) 
bone surface/bone volume (BS/BV), and H) connectivity density. n =4 per group. Mean with 95% 
CI. Differences assessed with unpaired T-test. *p<0.05, **p<0.01, ***p<0.001. 
 
In addition to increased numbers for x-ray analysis, histologic analysis of the fracture sites of 
diabetic and normal fracture healing and biomechanical strength testing are in process and/or 




4. Local and systemic teriparatide improve radiographic healing in diabetic mice, but only 
systemic teriparatide improves micro-CT healing parameters.  
Teriparatide has been extensively described as an anabolic bone agent that has potential to 
improve fracture healing (see: pages 49-50). The author tested the utility of locally-applied 
teriparatide via bioactive hydrogel among diabetic and normal mice, as well as systemic 
teriparatide injection.  After 28 days, HFHS mice treated with systemic teriparatide exhibited a 
mean RUST score of 10 (SD 0.89) compared to7.5 (SD 0.56) among untreated fracture sites, 
p=0.0014 (figure 30). After 28 weeks, HFHS mice treated with local PTH exhibited a mean RUST 
score of 10.25 (SD 0.95), p=0.0013 compared to untreated fracture. Micro-CT (n=4 per group) 
demonstrated improved micro-architecture of the HFHS fracture sites among groups treated with 
systemic teriparatide (PTH-S) compared to untreated fracture (FX) for bone density (bone 
volume/tissue volume),  30.41% PTH-S vs 14.1 FX, p=0.004; trabecular number 6.51/mm PTH-S 
vs 3.28/mm FX, p=0.0013; trabecular space, 0.17 mm PTH-S vs 0.33 FX , p=0.0025; and 
connectivity density, 542.6/mm3 PTH-S vs 208.2/mm3 FX, p=0.004 . No significant differences 
(p>0.05) were identified between PTH-S and FX groups in HFHS mice for trabecular thickness, 
0.069 mm PTH-S vs 0.054 mm FX; tissue mineral density, 865.2 g/cm3 PTH-S vs 891.9 g/cm3; 
and bone surface/bone volume, 44.81 mm2/mm3 vs HFHS 54.23 mm2/mm3. Local PTH treatment 
in HFHS mice resulted in no significant differences (p>0.05) between the local teriparatide group 
(PTH-L) and FX for any micro-CT parameter including: bone density, 20.2% PTH-L vs 14.1 FX; 
trabecular number 4.03/mm PTH-L vs 3.28/mm FX; trabecular space, 0.27 mm PTH-L vs 0.33 FX 
; connectivity density, 252.1/mm3 vs 208.2/mm3 FX; trabecular thickness, 0.060 mm PTH-L vs 
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0.054 mm FX; tissue mineral density, 906.5 g/cm3 PTH-L vs 891.9 g/cm3; and bone surface/bone 




Figure 30. Local teriparatide improves radiographic healing only, while systemic 
teriparatide improves radiographic healing and micro-CT callus parameters in mice fed a 
high fat, high sugar diet. (a) RUST score demonstrates improved radiographic healing in mice 
fed a high fat, high sugar diet (HFHS) after 28 days when treated with teriparatide systemically 
over 28 days (PTH-S) and locally (PTH-L) as a single dose at the time of fracture. Quantitative 
analysis of callus B) bone density (BV/TV), C) trabecular number (Tb.N), D) trabecular thickness 
(Tb.Th), E) trabecular space (Tb.Sp), F) connectivity density, G) tissue mineral density (TMD), 
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and H) bone surface/bone volume (BS/BV). n =4 per group. Mean with 95% CI. Differences 
assessed by ANOVA with multiple comparisons. *p<0.05, **p<0.01, ***p<0.001. 
 Further data is currently being collected and processed for this investigation including 
increased numbers for x-ray analysis, histology/immunohistochemistry, and biomechanical 
testing. 
 
5. Systemic administration of parathyroid hormone, along with systemic antibiotics, 
improves fracture healing in MRSA-infected fracture. 
Infection is a potentially devastating complication of fracture, and diabetic patients are at 
higher risk. These results demonstrate the effect of MRSA infection on a diabetic mouse model, 
and demonstrates the effectiveness of antibiotics alone and antibiotics with systemic teriparatide 
in improving fracture outcomes compared to sterile diabetic healing. 
  HFHS mice developed nonunion and profuse involucrum formation 28 days following 
fracture surgery and MRSA infection (figure 31). Mean RUST score of MRSA-infected fracture 
was 6 (SD 1.5), with zero out of 6 samples achieving radiographic union (figure 32). Micro-CT 
revealed “bone within bone” appearance of involucrum, or reactive bone, typical of chronic 
osteomyelitis (figure 31).  
Treatment with systemic, combinatory rifampin and vancomycin resulted in restored fracture 
healing, with significant radiographic improvement from baseline compared to uninterrupted 
sterile HFHS healing (figure 31, 32). A RUST score of 10.25 (SD 0.96) was achieved in the MRSA 
infection group treated with antibiotics alone (MRSA+ABX, p=0.012) and a RUST score of 9.75 
(SD 0.96) in the MRSA infection group treated with antibiotics and teriparatide 
(MRSA+ABX+PTH-S, p=0.038).  Callus formation was grossly restored on imaging compared to 
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sterile and infected HFHS samples (figure 30). Micro-CT analysis (n=4 per group) resulted in 
significant improvement between MRSA+ABX compared sterile HFHS healing (FX) for 
trabecular thickness, 0.084 mm MRSA+ABX vs 0.054 FX (p=0.015), and nonsignificant (p>0.05) 
trends toward improved callus parameters for bone density (bone volume/tissue volume),  23.93% 
MRSA+ABX vs 14.1% FX; trabecular number 4.06/mm MRSA+ABX vs 3.28/mm FX; trabecular 
space, 0.26 mm MRSA+ABX vs 0.33 FX; and connectivity density, 290.2/mm3 MRSA+ABX vs 
208.2/mm3 FX. MRSA+ABX+PTH-S demonstrated significant improvement of callus parameters 
compared to FX for bone density (28.06%, p=0.03), trabecular number (6.53/mm, p=0.0003), and 
trabecular space (0.1607 mm, p=0.0004), and connectivity density (452.4 /mm3, p=0.016). With 
multiple comparison’s test, MRSA+ABX+PTH-S demonstrated significant differences with 
improved healing over MRSA+ABX for trabecular number (p=0.0035) and trabecular space 
(p=0.0112). 
More data is currently being collected and processed for this investigation including increased 
numbers for x-ray analysis, histology/immunohistochemistry, and biomechanical testing.  
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Figure 31. 3-dimmensional reconstructions of tibiae 28 days after fracture in sterile and 
infected fracture healing treated with antibiotics and systemic teriparatide.  
Samples were harvested 28 days following fracture surgery and underwent 3-dimmensional 
micro-computed tomography (micro-CT) analysis. Sterile fracture (FX) in the high-fat, high sugar 
mouse model demonstrated poor healing and nearly absent callus formation. MRSA-infected 
fracture (MRSA) demonstrated profuse involucrum development, a hallmark of chronic 
osteomyelitis. Treatment of MRSA infection with combinatory vancomycin/rifampin antibiotic 
therapy (MRSA+ABX) for 3 days immediately following MRSA inoculation resulted in improved 
fracture healing compared to sterile fracture group. The addition of systemic teriparatide 
treatment (MRSA+ABX+PTH-S) further improved gross appearance of fracture healing.  
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Figure 31. Radiographic and micro-CT analysis of infected fracture sites treated with 
antibiotics and teriparatide demonstrate improved fracture healing after 28 days. 
Radiographic and micro-CT measurement of fracture callus among HFHS mice 28 days 
following fracture. RUST score is given (A) with quantitative micro-CT analysis of callus including 
B) bone density (BV/TV), C) trabecular number (Tb.N), D) trabecular thickness (Tb.Th), E) 
trabecular space (Tb.Sp), F) connectivity density, G) tissue mineral density (TMD), and H) bone 
surface/bone volume (BS/BV). Surprisingly, the presence of MRSA inoculation at the time of 
fracture, when treated with combinatory antibiotics for 3 days, appeared to have a positive effect 
on fracture healing, with improved RUST score and improved trabecular thickness on micro-CT. 
The addition of systemic teriparatide treatment allowed for improvement in trabecular number 
and trabecular space measurements. n =4 per group. Mean with 95% CI. Differences assessed by 








1. Rifampin-loaded hydrogels reduce bacteria load and improve fracture healing in a 
MRSA-infected, open fracture mouse model. 
Rates of surgical site infection following operative fixation has remained largely 
unchanged over the past 40 years [260]. New approaches are needed to combat infection after 
fracture.  The issues of antibiotic resistance and microbiome disturbances increase the importance 
of infection prevention and limiting systemic antibiotic use. In this study, we present a novel local 
antibiotic delivery method that reduces bacterial burden, decreases implant colonization, and 
improves fracture healing in mouse model of MRSA-contaminated, infected nonunion.   
Our results demonstrate that rifampin (300ug) hydrogel can suppress bacterial loads to 
nearly undetectable levels in the tissue fracture site after 3 days from infection. Rifampin (60ug) 
hydrogel were still able to reduce bacterial burden in our model by an average of 50% compared 
to non-treated MRSA infection. No bacteria were recovered from the implants after three days 
following high-dose local therapy. A wide range of bacterial cells were recovered from the implant 
(108-4201 CFU), likely due to the relatively short time for infection to establish biofilms. This 
variance resulted in limited statistical power in demonstrating an effect from the low-dose 
hydrogel, and improvements in sample number can be made in follow-up studies. 
Rifampin hydrogels also supported fracture healing with improved RUST score compared 
to MRSA-infected models. Although high-dose rifampin hydrogels were effective in reducing 
bacterial load to a near-zero level at the fracture site, we still observed an infected non-union rate 
of 50%. In contrast, nearly all MRSA-infected samples treated with high-dose systemic antibiotics 
demonstrated radiographic union, with a minimum RUST score of 8. We postulate that resulting 
infection following initial hydrogel treatment could be due to bacterial seeding of the surgical limb 
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that was not in the area of the fracture site and applied hydrogel. Conversely, while bacterial counts 
were not reduced to zero with the low-dose rifampin hydrogel, this hydrogel was still able to 
support fracture healing and improve radiographic union.  
Whereas previous studies have demonstrated efficacy of loading hydrogel with lysostaphin 
and gentamycin in animal models in combatting Staphylococcus aureus, our study is notable in 
that it is the first to our knowledge to study the efficacy of locally-applied, rifampin-loaded 
hydrogel to combat MRSA infection [114]14. 
In addition to demonstrating treatment efficacy, a major strength of our study is our 
clinically-relevant mouse model of post-traumatic infection. We used a challenging infection 
model including higher infective bacterial load and use of a resistant organism. Additionally, we 
introduced infection 10 minutes before hydrogel treatment was introduced to the infection site, as 
opposed to delivering bacteria within the antibiotic-containing hydrogel as previous authors have 
done [19]. Our infection model is clinically meaningful as it invariably progressed to nonunion, 
with hallmarks of osteomyelitis including involucrum characterized by profuse reactive bone 
formation. In addition to further fracture healing studies, we believe that further investigation of 
biologic pathways in our model could potentially lead to therapeutic strategies for bone 
regeneration and healing. 
 This present study is not without limitations. First, it is recognized that rifampin should 
not be used as systemic monotherapy due to rapid resistance. We chose to use rifampin in our 
study due to its ability to target intracellular bacteria and biofilms and its efficacy against MRSA, 
                                                     
14 A better understanding of elution kinetics of the rifampin-loaded hydrogel increases clinical 
usefulness of this data. Our lab has performed kinetic release experiments of rifampin from the 
hydrogel, however the author did not participate in any of these experiments and therefore has 
decided to not include the data here. 
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so as to be used as a potential adjunct to current antibiotic practice. Other rifampin-only local 
delivery methods, including mesh and powders, have been studied for local infection prevention 
strategies [261-262]. We believe our study adds to this existing body of literature by focusing on 
a delivery method that is readily applied and does not require surgical exposure. Rifampin has 
been demonstrated to be an effective local antibiotic and has been used in drug-eluting and 
antibiotic coated implants [263-264].  
Another potential limitation of rifampin-loaded hydrogels is that in vitro studies have 
demonstrated rifampin toxicity to osteogenic cells [265], raising concern about high-dose local 
rifampin therapy in the setting of fracture healing. Our data show no difference in radiographic 
healing between sterile fracture and the highest-dose rifampin treatment group, and exposure to a 
low dose of rifampin is not as effective in eliminating bacteria and improving healing. 
Additionally, previous in vivo studies using more than three-fold our maximum local rifampin dose 
demonstrated no deleterious effect on bone healing [262], with one study suggesting that rifampin 
can actually improve bone regeneration [266].  
 In summary, our study demonstrates that a rifampin-loaded hydrogel may be a useful 
therapy to compliment systemic antibiotic treatment after open fracture. Hydrogel can be readily 
applied without surgical exposure, demonstrating their potential especially in treating low-grade 
open injuries that do not require surgical debridement. A rifampin-loaded hydrogel may also help 
reduce the need for systemic antibiotic treatment, limiting microbiome disruption. Further studies 
are needed to investigate whether antibiotic-loaded hydrogel application can reduce infection rates 
and improve outcomes in the clinical setting. 
 
2. MRSA-infected fracture is marked by poor chondrocyte proliferation and maturation as 
well as IL-1 and NFKB inflammatory signaling 
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Histologic analysis and immunostaining revealed failure of chondrocyte proliferation and 
maturation in infected fracture, but chondrocyte differentiation was preserved. At 14 days, the 
sterile fracture sites demonstrated robust chondrocyte proliferation and bridging cartilage, whereas 
only scant chondrocytes were observed in the MRSA-infected cases. At 28 days, the 
chondrocyte/cartilage scaffold had largely been replaced by mineralized tissue, with only remnants 
of cartilage matrix apparent on Safranin O staining. Sox9 immunostaining was positive in both 
sterile fracture and infected samples, indicating chondrocyte differentiation in both conditions. 
However, RUNX2 staining was significantly diminished in infected healing. As RUNX2 
transcription is necessary for progression to the hypertrophic phase of chondrocyte differentiation, 
failure of RUNX2 transcription in the MRSA cases supports the conclusion that chondrocytes fail 
to mature in the setting of infection.  
The histological and immunohistochemical analysis highlights the both necessary and 
detrimental role of inflammation in the fracture healing process. For one, chondrocyte IL-1B and 
NF-KB expression are evident in sterile fracture healing, leading to the postulation that these 
inflammatory-related pathways are necessary for successful fracture healing. This finding upsets 
the idea of a strict demarcation of an “inflammatory” phase of fracture healing; even after the 
inflammatory phase is complete and soft callus bridging has occurred, inflammatory signaling via 
IL-1B and NF-KB is still observed. Nevertheless, overexpression of IL-B at the infected fracture 
site is associated with absence of proliferating cartilage and involucrum formation. Although the 
results presented here are limited in that causation cannot be proven from histologic analysis alone, 
they do strongly suggest the role of IL-1B in perpetuation of infected fracture non-union by failing 
to allow for the proliferation and maturation of chondrocytes at the fracture site.  
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This hypothesis that IL-1B is a major factor in preventing chondrocyte proliferation and 
maturation in infected fracture healing is supported by a large body of evidence that IL-1B is a 
major driver of cartilage damage in osteoarthritis (OA). While OA is traditionally thought of as a 
mechanical disease, inflammatory mediators including IL-1, tissue necrosis factor alpha, and toll-
like receptors have been identified as playing key roles in OA pathogenesis. The role of IL-1 as a 
key mediator of cartilage destruction in osteoarthritis was described by the early 1990s [267-268], 
and recent studies have focused on IL-1 and the IL-1 receptor as targets for inhibiting and 
preventing IL-1 related damage to cartilage and tissues [269-270]. A 2017 study used CRISPR to 
generate tissues resistant to inflammatory changes via targeted deletion of the IL-1 receptor [271]. 
The observation that the inflammatory IL-1B and NF-KB pathways are highly activated in 
sterile fracture healing raises a major clinical challenge in targeting infected nonunion. While 
antibiotics and bacterial elimination are the gold standard treatment for osteomyelitis, development 
of targeted therapeutics for promoting chondrocyte maturation in the setting of inflammatory 
fracture healing may be challenging. For one, our data, put in context of a large body of literature 
regarding IL-1 signaling and chondrocyte death, points to the possibility of targeting the IL-1B 
pathway to improve chondrocyte proliferation and maturation, and hopefully improve fracture 
healing in the setting of infection. Throughout this dissertation, both in literature review and with 
our original data, the importance of inflammatory pathways in fracture healing has been 
highlighted. Although infection results in an altered inflammatory environment, controlled 
inflammation and related signaling pathways are necessary for sterile fracture healing, beyond the 
initial hematoma/inflammatory phase. Therefore, inhibiting this process likely would impair the 
normal chondrocyte development and fracture healing. Therefore, the challenge of such an 
approach would depend on selectively targeting extracellular IL-1B and other inflammatory 
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mediators at the fracture site, while not interfering with intracellular signaling processes, or at least 
those that occur within the chondrocyte. This would potentially require an advanced delivery 
method or a molecular compound that could be transported to the fracture site without penetrating 
cartilage cells. 
Alternatively, in developing potential therapeutics for infected nonunion beyond antibiotics, 
these considerations highlight the potential role of anabolic agents as a potentially promising 
therapeutic strategy. We have demonstrated that, although chondrocyte proliferation is markedly 
reduced in our model, differentiation is still taking place; stimulating these cells to further 
proliferate despite an altered inflammatory environment may be a potentially valuable path of 
future investigation.  
While our immunostaining results provide insight into the molecular changes that occur at the 
callus site in infected fracture healing, our results do have limitations that need to be addressed. 
First, while our data present quite dramatic morphologic differences in chondrocyte differentiation 
and transcription factor expression, quantification of positive-staining cells and callus area would 
improve the quality and reproducibility of our results. Additionally, obtaining histology at various 
time points (7 days, 14 days, 21 days, 28 days) would help better qualify cellular development that 
occurs at the fracture site. Third, as previously mentioned, histologic study cannot definitively 
prove causation in biologic pathways; more advanced in vivo investigational techniques are 
required to draw more definite conclusions. 
In conclusion, although this study is relatively simple and has several limitations, it is helpful 
in providing a basic groundwork for future studies for therapies targeting infected nonunion. The 
results described point therapeutic efforts, in addition to antibiotic therapy, away from 
inflammation reduction and towards promoting anabolism and chondrocyte proliferation in the 
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infected fracture site. To this end, the next step that the author would like to pursue is investigating 
whether teriparatide can be used to enhance fracture healing in an infected fracture model. A 
limited investigation focused on diabetic mice is discussed later in this section.  
 
3. High-fat, high-sugar diet induces a mouse model of type 2 diabetes. 
This investigation into diabetic fracture healing and infection relied on a mouse model that 
was achieved by feeding a high-fat, high sugar diet for several months in order to obtain a diabetic 
phenotype. Mice exhibited important hallmarks of type 2 diabetes. First, they developed obesity, 
marked by a 160% increase in body fat compared to lean-fed, age-matched controls. As discussed 
in the introduction, obesity is considered to be the major risk factor for developing type 2 diabetes, 
although genetics also plays a role [115]. Our mouse model also demonstrates significantly 
impaired glucose tolerance, with glucose tolerance test results similar to those exhibited by Tallyho 
mice, a genetically-induced diabetic strain. The results of fasting blood glucose levels, however, 
were more modest. Although significant differences were identified between lean-fed and HFHS 
mice, the mean blood glucose levels in our study was approximately 180 mg/dL and mice rarely 
had levels greater than 200 mg/dL, even with a long-term feeding period of greater than 6 months. 
“Diabetic” mice are typically considered to have blood glucose levels in the 200-250 mg/dL range, 
although there are no widely-agreed upon cutoff values [272]. This is similar to previous author’s 
reports of the phenotype in diet-induced diabetic models achieving only a modest elevation in 
blood glucose level.  
 Although our diabetic mouse model presented with mild metabolic phenotype, it 
nevertheless accurately reflected challenges faced in orthopaedic surgical practice with diabetic 
patients. This raises the possibility that the cited range of greater than 250 mg/dL as being 
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“diagnostic” for diabetes in mice is too high. First, this study demonstrates that the chronic, diet-
induced diabetic model has increased susceptibility to MRSA infection, with significantly more 
bacteria recovered from fracture site tissues and implants three days following initial surgery and 
infection. Additionally, and perhaps most importantly, the present model demonstrates clearly 
impaired fracture healing, with decreased RUST scores and decreased micro-CT parameters after 
28 days compared to lean-fed, age-matched control mice. 
 Our diabetic mouse model holds distinct advantages over other models commonly used in 
the orthopaedic literature. A common means of modeling diabetes in mice is via streptozotocin 
injection (SZT), a chemical that preferentially targets and kills islet cells of the pancreas. 
Depending on dosing, SZT can be used to achieve a type 1 diabetic phenotype (high-dose) or a 
type 2 diabetic phenotype (low dose) [272]. Although widely used, this model has several distinct 
drawbacks, especially for modeling type 2 diabetes. First, this method does not incorporate obesity, 
a key component of diabetes pathogenesis. As discussed in the introduction, marrow fat and 
adipose cells have been found to play important regulatory roles in bone metabolism and signaling, 
many of which are still being discovered [26]. Thus, the SZT model is unable to provide insight 
into the role of adipose tissue in fracture healing and musculoskeletal disease. Additionally, it does 
not model insulin resistance, as target tissues are not subjected to chronic over-exposure to insulin. 
Third, this model tends to produce extreme phenotypes; even in modeling type 2 diabetes, 
investigators have reported mean blood glucose levels over 350 mg/dL [273]15. Such an extreme 
phenotype may limit clinical relevance of conclusions drawn from that model. 
 Genetic models of diabetes are the other most common means of studying diabetic bone 
disease. The Tallyho and Db/Db mouse strains are most prevalent. Tallyho is a multigenic diabetic 
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strain. Tallyho mice demonstrate elevated fasting blood glucose levels, impaired glucose tolerance. 
Db/Db mice are leptin-receptor deficient, and diabetes pathogenesis is caused by constant over-
eating. Db/Db mice exhibit extreme obesity, high fasting blood glucose levels, and impaired 
glucose tolerance. While Db/Db mice display poor fracture healing and are widely used in fracture 
healing studies, they are (based on the author’s experience) difficult to work with because they are 
prone to infection and die spontaneously after sterile surgical procedures at a very high rate. 
Considering their high cost, these mice are likely not ideal for infection studies that require a long 
time of follow-up because of an anticipated high mortality and low data yield. 
 In summary, our mouse model of diabetic fracture healing, like all other mouse models, 
has important strengths and limitations. Phenotypically, it exhibits key elements of type 2 diabetes, 
including obesity, impaired glucose tolerance, in increased blood glucose levels. As type 2 diabetes 
is typically a diet-associated disease, the pathogenesis is arguably more accurate than chemically-
induced and genetically-altered mouse models. It is a model that is prone to infection and, perhaps 
most importantly, exhibits poor fracture healing. The major drawback of our model, however, is 
that the elevation of blood glucose level is only modest compared to other models, resulting in a 
potentially less dramatic phenotype of diabetic bone disease. Additionally, our model is of chronic 
diabetes in aged mice, which improves the clinical relevance for fracture healing but means that 
our model is expensive and time-intensive; research using this model cannot happen quickly and 
must be done carefully and with careful planning. 
 
4. Fracture healing is improved by systemic and hydrogel-delivered teriparatide treatment 
in diabetic mice. 
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Our data demonstrates that intermittent, systemically administered teriparatide improved 
fracture healing in both HFHS and lean-fed mice. Systemic injection of teriparatide resulted in 
improved RUST score and micro-CT parameters in HFHS mice. Among lean-fed mice, RUST 
score did not significantly improve, as baseline RUST scores were already high with all samples 
achieving union with an average RUST of 11. Micro-CT parameters likewise were not 
significantly improved. 
While teriparatide is a powerful anabolic agent, systemic injection carries major 
drawbacks. First, teriparatide is an expensive agent and prohibitive for wide-spread use; although 
there have been no cost-benefit analyses to date, it would be infeasible to prescribe a month-long 
course of teriparatide to all diabetic fracture patients. As a protein, teriparatide cannot be 
administered orally and must be injected, contributing to patient inconvenience. Additionally, 
there is a theoretical concern that systemic injection of teriparatide may increase the risk of 
osteosarcoma due to its stimulation of pre-osteoblastic cells [274]. Thus, while a promising 
anabolic agent, different approaches to teriparatide administration may be needed to derive most 
cost-effective and patient-centered benefit.  
Therefore, testing a locally-applied, single dose administration of teriparatide-containing 
hydrogel is an important step in improving the clinical utility of teriparatide as a means of 
supporting fracture healing among patients at risk for non-union. Our data demonstrated that 
locally-applied teriparatide improved radiographic union score among HFHS mice. Although 
radiographic score demonstrated this benefit, micro-CT parameters were similar to the fracture-
only group.  
Overall, the data suggests that the anabolic activity of locally-applied teriparatide is not as 
potent as repeated systemic injection but may have clinical utility. While the idea of a one-time 
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dose of the anabolic agent at time of surgery to improve fracture healing is appealing, it is perhaps 
unsurprising that repeated dosing over the course of 28 days had greater effect on fracture healing. 
Our lab has tested in-vitro release kinetics of the teriparatide-containing hydrogel and 
demonstrated that virtually all of the teriparatide was eluted from the hydrogel after a few days.16 
Although a period of long-term release was demonstrated, it is therefore reasonable to assume that 
the effect of pre-osteoblast stimulation is relatively short lived in this model compared to repeated 
systemic injection. Another weakness of this experiment that should be addressed is that in this 
experiment there was no group of mice that received only the hydrogel without teriparatide. Since 
the hydrogel may act as a scaffold on which immune and progenitor cells may more efficiently 
bind and interact at the fracture site, the modest effect of improved fracture healing may be 
attributed to the presence of the hydrogel at the fracture site, with the teriparatide playing only a 
minor role, if any. To test this hypothesis, another group of HFHS mice would have been needed 
to undergo fracture surgery and treatment with hydrogel only. As only a limited number of HFHS 
mice were available for this phase of the study, this experiment should be performed in the next 
phase of follow-up studies to close this knowledge gap. 
5. Use of teriparatide to improve fracture healing in a MRSA-infected open fracture model 
in diabetic and normal mice. 
 This is the first study, to the author’s knowledge, to investigate infected fracture healing in 
using a diabetic mouse model. This has clinical importance, as diabetes is a major risk factor for 
post-traumatic infection as well as diminished fracture healing., as discussed in the introduction of 
this dissertation. It is the author’s hope that this work may lay the foundation for further 
investigation into treatment strategies in the setting of diabetic infected fracture. 
                                                     
16 The author did not participate in these experiments, therefore this data was not included in this dissertation.  
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This section of this dissertation was predicated on the hypothesis that introducing MRSA-
infection and treating with antibiotics would result in diminished fracture healing in diabetic mice. 
In the first section of this discussion, “Rifampin-containing hydrogels reduce bacteria load and 
improve fracture healing in a MRSA-infected, open fracture mouse model”, the observation was 
made that treated and cleared MRSA infection resulted in reduced fracture healing that healing 
parameters. This observation was made in other similar studies [264].  
Interestingly, however, this was not the observed result in diabetic mice. Following acute 
infection treatment with systemic antibiotics, RUST scores and micro-CT parameters improved; 
this result is being replicated in a second generation of experiments. This result is particularly 
surprising because, in contrast to our hypothesis, the presence and subsequent clearance of MRSA 
had an independent, positive effect on diabetic fracture healing. The author postulates two reasons 
for this observation: first, a potential osteogenic property of rifampin independent of its antibiotic 
effect, and second, altered inflammatory environment due to the presence of bacteria at the fracture 
site.  
As discussed earlier in this section (page 96), rifampin has several effects at the cellular 
and molecular level, which may result in improved fracture healing in diabetic mice. It is an 
interesting bioactive compound because of its ability to enter cells and bind to RNA polymerase 
[103,105]. Rifampin’s potential role in diminishing or augmenting fracture healing has been 
debated with conflicting evidence, with some authors demonstrating rifampin’s detrimental effect 
on mesenchymal progenitor cells [265] while others show a positive or neutral effect on bone 
healing, potentially through BMP signaling [266]. Therefore, injecting HFHS mice with high doses 
of rifampin over three days may have enhanced molecular and cellular signaling at the fracture 
site, resulting in improved fracture healing outcomes. Of note, vancomycin was also co-delivered 
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with rifampin. However, vancomycin is an unlikely candidate for modulating the fracture healing 
process as has been shown to have only neutral properties on mesenchymal stem cells in previous 
studies [265], and does not target transcription/translation pathways. 
To this end, a follow-up study was recently performed by injecting a series of diabetic mice 
with 3 days of rifampin (25mg/kg dose) following sterile fracture healing. Tissues have been 
harvested but x-ray and micro-CT results are pending. Although more follow-up studies are needed 
to evaluate histologic characteristics and biomechanics of the fracture site, this investigation poses 
a potentially exciting new avenue for improving fracture healing among diabetic patients using a 
drug that is already FDA approved and widely available. 
The other potential mechanism that could account for the improvement in fracture healing 
in the case of treated acute infection is an altered inflammatory environment at the fracture site 
due to the presence of bacteria and killed bacteria particles.  Despite the action of antibiotics which 
kill bacteria at the fracture site, killed bacteria debris would remain at the fracture site that would 
contribute to innate immune system signaling via PRRs and PAMPs (see introduction for a detailed 
discussion). This additional immune stimulation may potentially help recruit a more robust 
immune response without leading to the unchecked inflammatory response that is seen in the 
setting of infection. Further investigation into this effect would benefit from a set of experiments 
using killed bacteria to inoculate the diabetic fracture and observing resulting healing potential. 
The changes in the inflammatory milieu could by assessed by multiplex cytokine array. Further 
study of the effect of dead bacteria and inflammatory environment is warranted. 
Nevertheless, addition of intermittent teriparatide injection over the course of 28 days, in 
addition to initial antibiotic therapy, improved micro-CT parameters compared to antibiotic 
treatment alone.  This result is significant because, to our knowledge, it is the first time teriparatide 
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has been used to improve fracture healing in the setting of infection. However, the clinical 
relevance of this result is uncertain, as the teriparatide was administered with a powerful antibiotic 
combination that eliminated infection early in the healing process. The effect observed is likely 
similar to that of teriparatide in sterile fracture healing. 
To improve clinical relevance of our investigation of teriparatide in infected fracture 
healing, the author proposes an infection model with delayed treatment. For this experiment, 
fracture surgery would take place, with MRSA infection occurring at the time of surgery. 
Treatment would begin 5-7 days later, with systemic antibiotics to reduce the infective burden. 
Daily antibiotic administration would occur for 21 days, with daily teriparatide injection. Animals 
would be euthanized 28 days after surgery, and the quality of fracture healing would be compared 
among sterile fracture, untreated MRSA infection, infection with antibiotics, and infection with 
antibiotics and teriparatide. The hypothesis would be that systemic teriparatide injection improves 
fracture healing as assessed by RUST score, micro-CT, and mechanical strength testing. This 
experiment could be extended to aged diabetic mice for greater clinical relevance. 
The issue of infected fracture healing in diabetes is complex, with various inflammatory 
impetuses playing roles that are not fully understood. This very limited study demonstrates the 
potential for antibiotic and anabolic agents for improving fracture healing in case of infection. 
While more work needs to be done in the topic in order to draw more robust conclusions, there is 
potential for enhancing our clinical approaches to ultimately improve patient outcomes and move 
the field of fracture care forward. 
5. Inflammatory fracture healing: summary, conclusions and future directions. 
This dissertation provides fundamental data and methods for future studies in animal 
models and humans for improving outcomes in inflammatory fracture healing. This is an exciting 
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area of investigation because of its potential to improve patient outcomes and quality of life for 
many patients who receive orthopaedic care. That being said, this work is not without limitations 
and much more investigation is required.  
Infection following open fracture is a devastating complication. Early antibiotic 
administration is the cornerstone of early fracture care, but does not eliminate infection in all cases. 
The results of antibiotic-loaded hydrogel experiments support a potential new approach to 
reducing infective burden and improving fracture healing. It was demonstrated that rifampin-
loaded hydrogel reduces MRSA burden in an open fracture mouse model, the first study of its kind 
that the author is aware of in published literature to test antibiotic hydrogels on a resistant 
organism. In support of a recent paper submission, the author will be improving the clinical 
relevance of this data by testing a combinatory antibiotic hydrogel with rifampin and vancomycin. 
Nonunion poses a burden on patient quality of life and our healthcare system, with infection 
being an important cause of failed fracture healing. While antibiotic therapy is the cornerstone of 
infection treatment, new approaches to enhancing healing in the setting of infection should be 
investigated. The histological data presented in this dissertation has identified a key issue in 
infected fracture healing, cartilaginous callus formation in an altered inflammatory environment. 
Therapies that support callus formation through proliferation and maturation of cartilage may be 
beneficial. Anabolic therapies such as teriparatide may also be effective. The author has proposed 
an experimental design of using teriparatide to enhance fracture healing in a chronic infection 
model, a project that will likely begin in the spring of 2020. 
Diabetes is characterized by a pro-inflammatory state, with AGEs accumulation and 
activation of RAGE being key inflammatory factors contributing to diabetic bone disease. Diabetic 
patients are also more prone to infection. Currently, there are few therapies available for enhancing 
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fracture healing in diabetes that have strong clinical evidence. This dissertation has described a 
chronic, diet-induced diabetic mouse model that has been viable in studying diabetic fracture 
healing. This study attempted to use a local, teriparatide hydrogel to enhance fracture healing. 
Although the local teriparatide treatment improved radiographic healing, more investigation is 
required as to the effectiveness of this treatment and the role the hydrogel itself has as a biologic 
scaffold. Interestingly, the presence of MRSA infection treated by a systemic vancomycin-
rifampin therapy significantly improved healing. Current investigation is being performed as to 
whether rifampin alone or the presence of dead bacteria mediate this effect.  
In conclusion, this work, like most research projects, may have raised more questions than 
it answered. Despite this dissertation’s length, the author realizes its many limitations that require 
more data collection and further investigation. The author hopes that this work will allow some 
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[166] Wędrychowicz A,, Sztefko, Jerzy B. Starzyk. Sclerostin and its association with insulin  
resistance in children and adolescents Bone. 2019;120 232-238. 
[167] Follak N, Kloting I, Merk H. Influence of diabetic metabolic state on fracture healing in  
 124 
spontaneously diabetic rats. Diabetes Metab Res Rev. 2005;21:288-296. 
[168] Lee P, Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic  
pain. Arch Intern Med 2008;168:771–772 
[169] Lee PP, Feldman ZW, Ostermann J, et al. Longitudinal rates of annual eye examinations of  
persons with diabetes and chronic eye diseases. Opthalmology 2003;110:1952-1959.  
[170] Keegan T.H., Schwartz A.V., Bauer D.C., et al: Effect of alendronate on bone mineral  
density and biochemical markers of bone turnover in type 2 diabetic women: the fracture 
intervention trial. Diabetes Care 2004; 27: 1547-1553 
[171] Iwamoto J., Sato Y., Uzawa M., et al: Three-year experience with alendronate treatment in  
postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes  
Res Clin Pract 2011; 93: 166-173 
[172] Barrett-Connor E., Ensrud K.E., Harper K., et al: Post hoc analysis of data from the  
Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years  
of raloxifene treatment on glycemic control and cardiovascular disease risk factors in  
women with and without type 2 diabetes. Clin Ther 2003; 25: pp. 919-930 
[173] Vestergaard, P., Rejnmark, L. & Mosekilde, L. Are Antiresorptive Drugs Effective  
Against Fractures in Patients with Diabetes? Calcif Tissue Int 2011;88:209.  
[174] Lee YS, Gupta R, Kwon JT. Effect of a bisphosphonate and selective estrogen receptor  
modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat  
model. Spine J. 2018;18(10):1877-1887. 
[175] Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications  
trial/epidemiology of diabetes interventions and complications study at 30 years:  
overview. Diabetes Care 2014;37:9–16pmid:24356592 
 125 
[176] Vavanikunnel J, Charlier S, Becker C, et al. Association between glycemic control and risk  
of fracture in diabetic patients: A nested case-control study, The Journal of Clinical 
Endocrinology & Metabolism,  jc.2018-01879 https://doi.org/10.1210/jc.2018-01879 
[177] Neumann T, Sämann A, Lodes S, et al. Glycaemic control is positively associated with  
prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. 
Diabetic Medicine. 2011;28(7):872-875.  
[178] Schwartz A.V., Margolis K.L., Sellmeyer D.E., et al: Intensive glycemic control is not  
associated with fractures or falls in the ACCORD randomized trial. Diabetes Care 2012; 
35: pp. 1525-1531 
[179] Alblowi J, Kayal RA, Siqueira M, et al. High levels of tumor necrosis factor-alpha contribute  
to accelerated loss of cartilage in diabetic fracture healing.  Am J Pathol. 
2009;175(4):1574-85. 
 [180] Graves D, Alblowi J, Paglia D, O’Connor JP, Lin S . Impact of Diabetes on Fracture  
Healing Journal of Experimental & Clinical Medicine. 2011; 3(1):3-8. 
[181] Groop P, Forsblom C, Thomas MC. Mechanisms of Disease: pathway-selective insulin  
resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol 
Metab. 2005; 1(2):100-10. 
[182] Marcovecchio ML, Chiarelli F. Microvascular disease in children and adolescents with  
type 1 diabetes and obesity. Pediatr Nephrol (2011) 26:365. 
[183] Koike S, Yano S, Tanaka S, Sheikh A, Nagai A, Sugimoto T. Advanced glycation end-  
products induce apoptosis of vascular smooth muscle cells: a mechanism for vascular 
calcification. Int J Mol Sci. 2016; 17(9):1567.  
[184] Wang Z, Li L, Du R, Yan J, Liu N, Yuan W, et al. CML/RAGE signal induces  
 126 
calcification cascade in diabetes. Diabetol Metab Syndr. 2016; 8(1):83. 
[185] Bahney CS, Hu DP, Miclau T, Marcucio RS. The multifaceted role of the vasculature in  
endochondral fracture repair. Front Endocrinol. 2015; 5(6):4.1-10. 
[186] Wu W, Wang M, Sun Z, et al. The predictive value of TNF-alpha and IL-6 and the  
incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol  
2012;49: 3-7. 
[187] Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1  
diabetes mellitus. Nat Rev Endocrinol 2010;6: 158-66. 
[188] Kayal RA, Siqueira M, Alblowi J, et al. TNF-alpha mediates diabetes-enhanced  
chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis 
through FOXO1. J Bone Miner Res 2010;25: 1604-15. 
[189] Ko KI, Coimbra LS, Tian C, et al. Diabetes reduces mesenchymal stem cells in fracture  
healing through a TNFalpha-mediated mechanism. Diabetologia 2015;58: 633-642. 
[190] Lim JC, Ko KI, Mattos M, et al. TNFalpha contributes to diabetes impaired angiogenesis  
in fracture healing. Bone 2017;99: 26-38. 
[191] Kayal RA, Tsatsas D, Bauer MA, et al. Diminished bone formation during diabetic fracture  
healing is related to the premature resorption of cartilage associated with increased 
osteoclast activity. J Bone Miner Res 2007;22: 560-8. 
[192] Alblowi J, Tian C, Siqueira M, et al. Chemokine Expression is Upregulated in  
Chondrocytes in Diabetic Fracture Healing. Bone. 2013;53(1):294-300. 
[193] Xu MT, Sun S, Zhang L, et al. Diabetes mellitus affects the biomechanical function of the  
callus and the expression of TGF-beta1 and BMP2 in an early stage of fracture healing. 
Braz J Med Biol Res. 2016;49(1):1-8. 
 127 
[194] Jiang H, Wang Y, Meng J, et al. Effects of Transplanting Bone Marrow Stromal Cells  
Transfected with CXCL13 on Fracture Healing of Diabetic Rats. Cell Physiol Biochem. 
2018;49(1):123-133. 
[195] Hoff P, Gaber T, Strehl C, et al. Immunological characterization of the early human  
fracture hematoma. Immunol Res 2016;64: 1195-1206. 
[196] Liuni FM, Rugiero C, Feola M, et al. Impaired healing of fragility fractures in type 2  
diabetes: clinical and radiographic assessments and serum cytokine levels. Aging Clin 
Exp Res 2015;27 Suppl 1: S37-44. 
[197] Gortler H, Rusyn J, Godbout C, et al. Diabetes and Healing Outcomes in Lower Extremity  
Fractures: A Systematic Review. Injury. 2018 Feb;49(2):177-183. 
[198] Ganesh S, Pietrobon R, Cecilio W, et al. The Impact of Diabetes on Patient Outcomes After  
Ankle Fracture. J Bone Joint Surg Am. 2005;87(8):1712-8. 
[199] Thakeb M. Treatment of complicated distal tibial fractures in diabeticPatients. Egyptian  
Orthopedic Journal. 2013; 48:145–150 
[200] Abdelgaid SM, Moursy AF, Elgebaly EA, et al. Minimally Invasive Treatment of Ankle  
Fractures in Patients at High Risk of Soft Tissue Wound Healing Complications. J Foot 
Ankle Surg. 2018;57(3):557-571. 
[201] Liu J, Ludwig T, Ebraheim NA. Effect of the blood HbA1c level on surgical treatment  
outcomes of diabetics with ankle fractures. Orthop Surg. 2013 Aug;5(3):203-8.  
[202] Beam H, Parsons RJ,  Lin SS. The effects of blood glucose control upon fracture healing in  
the BB Wistar rat with diabetes mellitus. Journal of Orthopaedic Research. 20(6) 2002: 
1210-1216. 
[203] Kayal RA, Alblowi J, McKenzie E, et al. Diabetes causes the accelerated loss of cartilage  
 128 
during fracture repair which is reversed by insulin treatment.  Bone. 2009;44(2):357-63. 
[204] Follak N, Kloting I, Merk H. Influence of diabetic metabolic state on fracture healing in  
spontaneously diabetic rats. Diabetes Metab Res Rev. 2005;21:288-296. 
[205] Liu GY, Cao G, Tian FM, et al. Parathyroid hormone (1-34) promotes fracture healing in  
ovariectomized rats with type 2 diabetes mellitus. Osteoporosis Int. 2017;28(10):3043- 
3053.  
[206] Gandhi A, Beam HA, O'Connor JP, et al. The effects of local insulin delivery on diabetic  
fracture healing. Bone. 2005;37(4):482-90. 
[207] Okabayashi T, Shima Y, Sumiyashi T, et al. Intensive versus intermediate glucose control  
in surgical intensive care unit patients. Diabetes Care. 2014;37(6):1516-24. 
[208] Bilotta F, Spinelli A, Giovannini F, et al. The effect of intensive insulin therapy on infection  
rate, vasospasm, neurologic outcome, and mortality in neurointensive care unit after 
intracranial aneurysm clipping in patients with acute subarachnoid hemorrhage: a 
randomized prospective pilot trial. J Neurosurg Anesthesiol. 2007;19(3):156-60.  
[209] Lazar HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in diabetic coronary  
artery bypass graft patients improves perioperative outcomes and decreases recurrent  
ischemic events. Circulation. 2004;109(12):1497-502.  
[210] Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive-care  
unit by strict glycemic control. Endocr Pract. 2004;10 Suppl 2:46-52.  
[211] Kang ZQ, Huo JL, Zhai XJ. Effects of perioperative tight glycemic control on  
postoperative outcomes: a meta-analysis. Endocr Connect. 2018;7(12):R316-R327. 
[212] Yang L, Sun Y, Li G, et al. Is hemoglobin A1c and perioperative hyperglycemia predictive  
 129 
of periprosthetic joint infection following total joint arthroplasty?: A systematic review 
and meta-analysis. Medicine (Baltimore). 2017;96(51):e8805. 
[213] Humphers J, Shibuya N, Fluhman BL, et al. The Impact of Glycosylated Hemoglobin and  
Diabetes Mellitus on Wound-Healing Complications and Infection After Foot and Ankle  
Surgery. Journal of the American Podiatric Medical Association  2014; 104(4) 320-329.  
[214] Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on  
fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl 
J Med. 2001;344(19):1434.  
[215] Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid  
hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women 
with osteoporosis: a randomized trial. Ann Intern Med. 2007;146(5):326.  
[216] Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1–84 accelerates fracture- 
healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg. 2011;93:1583–
1587. 
[217] Aspenberg P, Genant H K, Johansson T, et al. Teriparatide for acceleration of fracture  
repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal 
women with distal radial fractures. J Bone Miner Res 2010; 25(2): 404-14. 
[218] Johansson, Torsten. PTH 1-34 (teriparatide) may not improve healing in proximal humerus  
fractures. A randomized, controlled study of 40 patients. Acta orthopaedica 2015; 87(1) 
79-82. 
[219] Chalidis B, Tzioupis C, Tsiridis E, et al. Enhancement of fracture healing with parathyroid  
hormone: preclinical studies and potential clinical applications. Expert Opin Investig 
Drugs 2007; 16(4): 441-9. 
 130 
[220] Ardura JA, Portal-Núñez S, Lozano D, et al. Local delivery of parathyroid hormone-related  
protein-derived peptides coated onto a hydroxyapatite-based implant enhances bone 
regeneration in old and  diabetic rats. J Biomed Mater Res A. 2016;104(8):2060-70. 
[221] Hamann C, Picke AK, Campbell GM, et al. Effects of parathyroid hormone on bone mass,  
bone strength, and bone regeneration in male rats with type 2 diabetes mellitus.  
Endocrinology. 2014;155(4):1197-206. 
[222] Massari, L., Benazzo, F., Falez, F. et al. Biophysical stimulation of bone and cartilage:  
state of the art and future perspectives. Int Orthop. 2019. 
https://doi.org/10.1007/s00264-018-4274-3. 
[223] Thomas K. Kristiansen; John P. Ryaby; Joan McCabe; et al. Accelerated Healing of Distal  
Radial Fractures with the Use of Specific, Low-Intensity Ultrasound. A Multicenter,  
Prospective, Randomized, Double-Blind, Placebo-Controlled Study. JBJS Am. 1997; 
79(7):961-973. 
[224] Busse JW, Kaur J, Mollon B, Bhandari M, Tornetta P, et al. Low intensity pulsed  
ultrasonography for fractures: systematic review of randomised controlled trials. BMJ. 
2009; 338:b351. 
[225] Ebrahim S, Mollon B, Bance S. Low-intensity pulsed ultrasonography versus electrical  
stimulation for fracture healing: a systematic review and network meta-analysis. Can J 
Surg. 2014 Jun;57(3):E105-18. 
[226] Busse JW, Bhandari M, Einhorn TA, et al. TRUST Investigators writing group. Re- 
evaluation of low intensity pulsed ultrasound in treatment of tibial fractures (TRUST):  
randomized clinical trial. BMJ 2016;355:i5351. 
[227] Saxena A, DiDomenico LA, Widtfeldt A, et al. Implantable Electrical Bone Stimulation  
 131 
for Arthrodeses of the Foot and Ankle in High-Risk Patients: A Multicenter Study. The 
Journal of Foot and Ankle Surgery.2005; 44(6):450-454. 
[228] Jason R. Hanft, John P. Goggin, Adam Landsman, et al. The role of combined magnetic  
field bone growth stimulation as an adjunct in the treatment of neuroarthropathy/charcot 
joint: An expanded pilot study. The Journal of Foot and Ankle Surgery, 1998; 37(6). 
[229] Akyol UK, Güngörmüş M. Effect of biostimulation on healing of bone defects in diabetic  
rats. Photomed Laser Surg. 2010;28(3):411-6. 
[230] Cai, J., Li, W., Sun, T. et al. Pulsed electromagnetic fields preserve bone architecture  
and mechanical properties and stimulate porous implant osseointegration by promoting  
bone anabolism in type 1 diabetic rabbits Osteoporos Int 2018;29: 1177.  
[231] X. Li, M.S. Ominsky, K.S. Warmington, et al. Sclerostin antibody treatment increases  
bone formation, bone mass, and bone strength in a rat model of postmenopausal 
osteoporosis. JBMR 2009;24:78-588 
[232] Padhi D, Jang G, Stouch B. Single-dose, placebo-controlled, randomized study of AMG  
785, a sclerostin monoclonal antibody. JBMR 2011;26: 19-26. 
[233] Picke AK, Salbach-Hirsch J, Hintze V, et al. Sulfated hyaluronan improves bone  
regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function. 
Biomaterials. 2016;96:11-23. 
[234] Dedania J, Borzio R, Paglia D, et al. Role of local insulin augmentation upon allograft  
incorporation in a rat femoral defect model. J Orthop Res 2011; 29: 92-99. 
[235] Park AG, Paglia DN, Al‐ Zube L. Local insulin therapy affects fracture healing in a rat  
model. J. Orthop. Res. 2013;31:776-782.  
[236] Filion TM, Skelly JD, Huang H, et al. Impaired osteogenesis of T1DM bone marrow-derived  
 132 
stromal cells and periosteum-derived cells and their differential in-vitro responses to 
growth factor rescue. Stem Cell Res Ther. 2017;8(1):65. 
[237] Khorsand B, Nicholson N, Do AV, et al. Regeneration of bone using nanoplex delivery of  
FGF-2 and BMP-2 genes in diaphyseal long bone radial defects in a diabetic rabbit model. 
J Control Release. 2017;248:53-59. 
[238] Al-Zube L, Breitber EA, O'Connor JP, et al. Recombinant Human Platelet-Derived Growth  
factor(rhPDGF-BB) and beta-Tricalcium Phosphate/Collagen Matrix Enhance Fracture  
Healing in a Diabetic Rat Model. J Orthop Res 2009; 27(1): 1-12 
[239] Azad V, Breitbart E, Al-Zube L, et al. rhBMP-2 enhances the bone healing response in a  
diabetic rat segmental defect model. J Orthop Trauma. 2009;23(4):267-76. 
[240] Liu R, Biirke O, Morse A, et al. Myogenic progenitors contribute to open but not closed  
fracture repair. BMC Musculoskelet Disord 2011;12:288. 
[250] Schindeler A, Morse A, Harry L, et al. Models of tibial fracture healing in normal and Nf1- 
deficient mice. J Orthop Res 2008;26(8):1053-60. 
[251] Stavrakis AI, Niska JA, Shahbazian JH, et al. Combination prophylactic therapy with  
rifampin increases efficacy against an experimental Staphylococcus epidermidis 
subcutaneous implant-related infection. Antimicrob Agents Chemother 2014;58(4): 2377-
2386.  
[252] Hu Y, Hegde V, Johansen D, et al. Combinatory antibiotic therapy increases rate of  
bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus 
spinal implant infection. PLoS ONE 2017;12(2): e0173019. 
[253] Niska JA, Shahbazian JH, Ramos RI, et al. Vancomycin-Rifampin Combination Therapy  
Has Enhanced Efficacy against an Experimental Staphylococcus aureus Prosthetic Joint  
 133 
Infection. Antimicrob Agents Chemother 2013;57(10):5080-5086. 
[254] M.J. Patzakis, J. Wilkins. Factors influencing infection rate in open fracture wounds. Clin  
Orthop Relat Res 1989;(243): 36-40 
[255] Templeman DC, Gulli B, Tsukayama DT, et al. Update on the management of open  
fractures of the tibial shaft. Clin Orthop Relat Res 1998;350:18-25. 
[256] Fiset S, Godbout C, Crookshank MC, et al. Experimental validation of the radiographic  
union score for tibia fractures (RUST) using micro-computed tomography scanning and  
biomechanical testing in an in-vivo rat model. J Bone Joint Surg Am 2018;100(21):1871-
8.  
[257] Litrenta J, Tornetta P, Ricci W, et al. In vivo correlation of radiographic scoring  
(radiographic union scale for tibia fractures) and biomechanical data in a sheep  
osteotomy model: can we define union radiographically? J Orthop Trauma 
2017;31(3):127-130. 
[258] Bouxsein ML, Boyd SK, Christiansen BA, et al. Guidelines for assessment of bone  
microstructure in rodents using micro-computed tomography. J Bone Min Res. 2010; 
25(7):1468-1486. 
[259] Hevroni A, Koplewiitz BZ. Images in clinical medicine. Bone within bone – chronic  
osteomyelitis. N Engl J Med. 2007;356(8):e7. 
[260] Willey M and Karam M. Impact of infection on fracture fixation. Orthop Clin North Am  
2016;47(2):357-364. 
[261] Reinbold J, Hierlemann T, Urich L, et al. Biodegradable rifampicin-releasing coating of  
surgical meshes for the prevention of bacterial infections. Drug Des Devel Ther  
2017;11:2753-2762 
 134 
[262] Shiels, S. M., Tennent, D. J., Lofgren, A. L. and Wenke, J. C. Topical rifampin powder  
for orthopaedic trauma part II: Topical rifampin allows for spontaneous bone healing in  
sterile and contaminated wounds. J Orthop Res 2018;36(12): 3142-3150. 
[263] Suhardi VJ, Bichara DA, Kwok S, et al. A fully functional drug-eluting joint implant. Nat  
Biomed Eng 2017; 1:0080. 
[264] Ashbaugh AG, Jiang X, Zheng J, et al. Polymeric nanofiber coating with tunable  
combinatorial antibiotic delivery prevents biofilm associated infection in vivo. Proc Natl  
Acad Sci USA 2016; 113(45):E6919-28. 
[265] Rathbone CR, Cross JD, Brown KV, et al.  Effect of various concentrations of antibiotics  
on osteogenic cell viability and activity. J Orthop Res 2011;29(7):1070-1074. 
[266] Durmuşlar MC, Balli U, Türer A et al. Radiological and Stereological Evaluation of the  
Effect of Rifampin on Bone Healing in Critical-Size Defects. J Craniofac Surg.  
2016;27(6):1481-5. 
 [267] Van den Berg WB, van de Loo FA, Otterness I, et al. In vivo evidence for a key role of  
IL-1 in cartilage destruction in experimental arthritis. Agents Actions Suppl. 1991;32:159- 
63. 
[268] Rainsford KD. Doxorubicin is a potent inhibitor of interleukin 1 induced cartilage  
proteoglycan resorption in-vitro. J Pharm Pharmacol. 1989;41(1):60-3. 
[269] Kar S, Smith DW, Gardiner BS, Grodzinsky AJ. Systems based study of the therapeutic  
potential of small charged molecules for the inhibition of IL-1 mediated cartilage  
degradation. PLoS One. 2016;11(12):e0168047. 
[270] Zuo S, Zou W, Wu RM. Icariin alleviates IL-1B-induced matrix degradation by activating  
the Nrf2/ARE pathway in human chondrocytes. Drug Des Devel Ther. 2019 21;13:3949- 
 135 
3961.  
[271] Brunger JM, Zutshi A, Willard VP et al. CRISPR/Cas9 editing of murine induced  
pluripotent stem cells for engineering inflammation-resistant tissues. Arthritis Rheumatol.  
2017;69(5):1111-1121. 
[272] Fajardo RJ, Karim L, Calley V, Bouxsein ML. A review of rodent models of type 2  
diabetic skeletal fragility. J Bone Min Res. 2014;29(5):1025-1040. 
[273] Mao L, Tamura Y, Kawao N, et al. Influence of diabetic state and vitamin D deficiency on  
bone repair in female mice. Bone. 2014; 61:102-108. 
[274] Andrews EB, Gilsenan A, Midkiff K, Harris D. Challenges in studying very rare cancer  
outcomes and infrequent exposures: example of teriparatide and osteosarcoma. Ann  
Epidemiol. 2016;26(11):751-753. 
 
